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Abstract 
 Glucocorticoid-induced hyperglycemia (GCIH) has been associated with negative patient 
outcomes.  Oncology inpatients are particularly affected by GCIH, as they are prescribed high-
dose glucocorticoids (GC) during their hospitalization.  Yet, organizational data highlights 
variability in treatment, suboptimal glycemic control, and a gap in the timeliness of therapy.   
The purpose of this Doctor of Nursing Practice (DNP) project was to improve GCIH assessment 
and management for oncology inpatients receiving GCs.  The Iowa model was used as the 
guiding framework for translating evidence into clinical decision-making for this project.   
An evidence-based protocol that included a Best Practice Advisory (BPA) within the 
electronic medical record and a standardized algorithm was developed and implemented.  The 
goal was to immediately initiate blood glucose monitoring (BGM) and sliding scale insulin (SSI) 
therapy in concurrence with a GC order to promptly detect and treat GCIH, thereby reducing 
uncontrolled hyperglycemia rates.  Average length of stay (ALOS) days were also evaluated to 
assess for any correlations with Diabetes Team consults and uncontrolled hyperglycemia rates. 
 The sample group within a four-month period comprised of 49 patients with hematologic 
malignancies who were prescribed GCs.  The results revealed an improvement in BGM orders, 
Diabetes Team consults that met criteria, total uncontrolled hyperglycemia episodes, and 
hypoglycemic events.  There was a decrease in SSI orders and an overall increase in ALOS by 
six days.  A trend in more prolonged hospitalizations was noted in patients with uncontrolled 
hyperglycemia.   
The data was not strong enough to produce conclusions for both process and impact 
evaluations.  It is possible that a Hawthorne effect occurred as a result of a recurrent discussion 
 v 
of this project at multiple meetings.  It is challenging to infer a direct correlation of ALOS with 
Diabetes Team consults due to many potential influential factors.   
Improvement in GCIH detection and management resulted in a reduction of uncontrolled 
hyperglycemic episodes.  Further benefits associated with GCIH management need to be 
explored with larger samples. 
 Limitations included sample size and time, patient right to refusal of care, staffing 
considerations, variance in clinical judgment and preferences for administrative autonomy, and 
factors impacting ALOS and hyperglycemia.  
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CHAPTER 1. EXECUTIVE SUMMARY 
Introduction 
Background/Problem 
 Glucocorticoid-induced hyperglycemia (GCIH) has been associated with negative 
outcomes and treatment-related morbidities.  Oncology inpatients are among the most affected 
populations of GCIH, as they are often prescribed high-dose glucocorticoids (GC).  Rates of 
blood glucose monitoring (BGM) and appropriate management for GCIH remain low or 
inconsistent.  The purpose of this Doctor of Nursing Practice (DNP) project was to improve 
GCIH assessment and management to reduce the rates of uncontrolled hyperglycemia (>180 
mg/dl) experienced by the inpatient population with hematological malignancies receiving GCs. 
Conceptual Framework 
  The Iowa model by Titler et al. (2001) is a seven-step guide for translating evidence into 
practice and clinical decision-making.  The seven steps are: 1) Select a topic based on problem 
and knowledge-focused triggers, 2) Form a team, 3) Assemble critique and synthesize the 
literature, 5) Develop practice change, 6) Implement the change, and 7) Evaluate the change. 
Literature Review and Synthesis 
  Mosby’s Quality of Evidence (Melnyk, 2004) and the Appraisal of Guidelines for 
Research and Evaluation (AGREE) II instrument (Brouwers et al., 2013) were used to grade the 
evidence of 21 synthesized articles.  The themes from the literature that were specifically 
recognized for this DNP project include: 1) GCIH prevalence, 2) Definition of hyperglycemia, 3) 
Effects of hyperglycemia on patient outcomes, 4) BGM protocols for GCIH, and 5) Treatment 
for GCIH.   
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Innovation/Objectives 
The most appropriate strategy to address GCIH was the implementation of an evidence-
based (EB) protocol to standardize the assessment and management of GCIH.  The goal was to 
immediately initiate BGM and sliding scale insulin (SSI) therapy in concurrence with a GC 
order, thereby aiding in the prompt detection and treatment of GCIH.  It was expected that the 
prolongation of untreated hyperglycemia would be reduced, which subsequently had the 
potential to decrease uncontrolled hyperglycemia rates and improve clinical patient outcomes 
such as average length of stay (ALOS). 
Methods 
Practice Change Description 
The current process involves inconsistent practice in ordering BGM, insulin, and 
Diabetes Team consults for patients that had GC orders.  This inconsistency would be addressed 
through the implementation of an electronic Best Practice Advisory (BPA) within the patient’s 
medical record that notified providers and nurses to place the orders for BGM and insulin as 
soon as GC therapy was initiated.  The protocol additionally provided guidance in GCIH 
management through an algorithm that notes when to escalate care to the Diabetes Team, based 
on established BG level readings.      
Setting and Sample 
The project was implemented on two inpatient oncology units within a large tertiary care 
hospital in Hawai’i.  The sample population criteria consisted of adult inpatients with 
hematologic malignancies receiving GCs, who were admitted or transferred to and discharged 
from either of the two oncology units.  
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Data Collection 
 The data elements of the impact evaluation were uncontrolled hyperglycemia rates and 
ALOS days; as for the process evaluation, the data elements were the number of BGM orders, 
insulin orders, and Diabetes Team consults.  Data collection incorporated running data sets based 
on the established codes that reflect the specified population in regards to the desired variables 
over a designated four-month time frame.   
Results 
Description of Participants 
 The baseline group consisted of 75 patients who met criteria between April 1, 2017 and 
July 31, 2017.  The post-implementation group was comprised of 49 patients who met criteria 
between September 1, 2017 and December 31, 2017.  
Data Analyses Findings 
The process evaluation revealed a 3% increase in BGM orders, an 8% increase in 
Diabetes Team consults, and a 7% decrease in insulin orders.  An improvement in Diabetes 
Team consults that appropriately met criteria was supported by a 54% increase in the number of 
uncontrolled hyperglycemia episodes with a Diabetes Team consult.  The impact evaluation 
presented a 3% decrease in total uncontrolled hyperglycemia episodes and an overall ALOS 
increase by six days in both groups with and without a Diabetes Team consult.  A trend of 
prolonged hospitalization was also noted in the patients with uncontrolled hyperglycemia in 
comparison to the patients with controlled glycemic levels.    
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Discussion 
Interpretation of Results 
Overall, with the resulting sample size of 49, trends can be noted, however, the data is not 
strong enough to produce conclusions for both process and impact evaluations.  It is possible that 
a Hawthorne effect occurred as a result of attendance and discussion of the project at multiple 
oncology committee meetings and oncology staff meetings throughout 2017.  The decreasing 
trend in insulin orders could be attributable to the provider’s concern for hypoglycemia, a 
frequent concern discussed in meetings.  The low number of consults could infer that patients are 
not reaching the >180 mg/dl BG level, the advised criteria for consults.  The decrease in total 
oncology unit patients with BG levels greater than 180 mg/dl could indicate the positive impact 
of the GCIH protocol.  It is challenging to conclude a direct correlation between the presence of 
a Diabetes Team consult or lack thereof with ALOS. 
Implications 
EB standards of care, clinical judgment, and collaborative professional relationships were 
utilized to produce and implement a standardized GCIH protocol.  This protocol was essential to 
increase awareness of GCIH and empower staff to proactively assess and manage GCIH.  
Improvement in GCIH detection and management resulted in a reduction in the rates of 
uncontrolled hyperglycemic episodes.  Further benefits associated with GCIH management 
needs to be explored. 
Limitations 
 Despite efforts to account for risks, there are factors in addition to the proposed protocol 
that may influence outcomes.  These limitations included sample size and time, patient right to 
refusal of care, staffing considerations, variance in clinical judgment and preferences for 
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administrative autonomy, and factors impacting ALOS.  Within the setting of a quality 
improvement initiative, it is not realistic that all conditions can be controlled.   
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CHAPTER 2. PROBLEM 
Introduction 
Hyperglycemia is a common complication of GC therapy, regardless of a patient’s 
previous history of diabetes mellitus (DM).  Oncology inpatients are frequently treated with GCs 
in concurrence with their cancer treatment.  GCIH has been associated with negative outcomes 
and treatment-related morbidities.  Despite this knowledge, rates of BGM and appropriate 
management for GCIH remain low or inconsistent.  The purpose of this DNP project was to 
improve GCIH detection and management and reduce the rates of uncontrolled hyperglycemic 
episodes experienced by the inpatient oncologic population receiving GCs.  This chapter will 
review the background of GCIH; describe the literature search, critique and synthesis; and 
conclude with a recommended EB protocol. 
Background/Problem 
The American Association of Clinical Endocrinologists and American Diabetes 
Association define hospital-related hyperglycemia as a BG reading greater than 140 mg/dl, at 
any given time during hospitalization (The American Diabetes Association, 2015; Magaji & 
Johnston, 2011).  Hyperglycemia is prevalent in 38% to 46% of non-critically ill inpatients and 
in approximately 80% of critically ill and cardiac surgery patients (Corsino, Dhatariya, & 
Umpierrez, 2014; Gomez & Umpierrez, 2014).  There is a vast body of evidence that supports 
the fact that hyperglycemia, independent of a patient’s history of DM, is associated with poor 
clinical patient outcomes.  A few days of hyperglycemia - also referred to as transient 
hyperglycemia - can be linked to increased risks of mortality and incidences of infection, 
deleterious effects on the immune system, prolonged hospital stays, higher admission rates to the 
intensive care unit, and increased disability after discharge that warrants a greater need for 
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transitional or nursing home care (Corsino et al., 2014; Umpierrez et al., 2012).  Interestingly, 
increasing evidence indicates that new-onset hyperglycemia in hospitalized patients without a 
preexisting diabetic history has led to greater complications and in-hospital mortality rates than 
in those with a prior history of DM (Buehler et al., 2015; Corsino et al., 2014; Koskela, Salonen, 
Romppanen, & Niskanen, 2014). 
Medications that induce hyperglycemia, such as GCs, are one of the main etiologies of 
elevated BG levels in the inpatient setting (Corsino et al., 2014; Seheult et al., 2014; Tamez-
Pérez, Quintanilla-Flores, Rodriguez-Gutierrez, Gonzalez-Gonzalez, & Tamez-Pena, 2015).  
GCs have profound effects on glucose metabolism, causing a decrease in both insulin secretion 
and insulin sensitivity (Gonzales-Gonzalez et al., 2013).  Although it is to be expected that BG 
levels in a non-diabetic patient would return to euglycemic levels subsequent to the withdrawal 
of the hyperglycemia-provoking agent, this is not always the case with GCs.  GC therapy can 
exacerbate hyperglycemia in patients with known DM.  In addition, GCs can elevate BG 
readings to nearly 68% higher than baseline levels, permanently induce hyperglycemia, and 
cause DM in over 50% of patients without a prior history of DM or hyperglycemia (Gonzalez-
Gonzalez et al., 2013; Tamez-Pérez et al., 2015; Perez et al., 2014).   
Regardless of the GC-related risks, more than 12% of hospitalized patients in the nation 
are prescribed high-dose GCs; however, rates of BGM and appropriate management continue to 
be very low (Dhatariya, 2014).  For example, a prevalence study conducted over two consecutive 
days by Narwani, Swafe, Stavraka, and Dhatariya (2014) found that of 120 patients being treated 
with GCs, only 25 patients were receiving routine BGM during their hospital stay.  
Cancer patients are among the most affected populations of GCIH, as they are often 
prescribed high-dose GCs during their hospitalization for a number of therapeutic reasons: as a 
   
8 
component of their chemotherapy, as an appetite stimulator, and for the management of nausea 
and vomiting, control of tumor-associated pain, and reduction of cerebral edema (Brady, Grimes, 
Armstrong, & LoBiondo-Wood, 2014; Dietrich, Rao, Pastorino, & Kesari, 2011).  Unfortunately, 
along with these benefits come not only the aforementioned effects of hyperglycemia, but also 
negative impacts on diagnostic imaging studies, the development and progression of cancers, and 
alterations of treatment responses (Storey & Von Ah, 2015).   
GC therapy may be administered in different doses through a variety of routes, but it is 
most often administered as a single daily morning regimen.  Within four to eight hours of the 
administration of an oral dose - and sooner with intravenous routes - this morning regimen 
causes predictable rises in BG levels, leading to postprandial elevations in glycemic levels in the 
late morning through the afternoon (Brady et al., 2014; Corsino et al., 2014).  Overnight, BG 
levels typically stabilize, returning to baseline levels by the next morning (Corsino et al., 2014).  
As a result, elevated levels are not always reflected in the patient’s fasting BG levels in the 
morning, either through BGM or a basic metabolic panel blood test.  This means that there is 
potential for GCIH to go unnoticed in patients without a pre-existing DM diagnosis, as well as 
patients who may not have orders for scheduled BGM throughout the day.  Further, GCIH may 
also be overlooked as a treatment priority, as the medical treatment plan will naturally be 
targeted at the patient’s presenting symptoms or admission diagnoses.       
The physicians at the outpatient Cancer Center initially raised the issue of GCIH after 
noting an increasing trend in hyperglycemia in their oncology patients who were receiving GCs 
as part of their chemotherapy regimen.  In March 2016, the Cancer Center contacted the inpatient 
Diabetes Team, as well as a partnering Cancer Center in Texas, to inquire about management 
guidelines specific to GCIH.  It was then realized that there was no such protocol in place in the 
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inpatient and outpatient settings within the organization for the assessment and management of 
GCIH.  EB guidelines established by the Endocrine Society advise BGM for at least 24-48 hours 
for patients who are prescribed GCs (Umpierrez et al., 2012).  In addition, the initiation of 
hyperglycemia management should be conducted as necessary for consistent BG levels >140 
mg/dl (Umpierrez et al., 2012).  Furthermore, the Joint Commission Advanced Disease-Specific 
Care for Inpatient Diabetes Care requires BGM protocols and individualized plans for 
hyperglycemia treatment (Isbey, Gomez, & Mooney, 2013). 
In response to the inquiry by the Cancer Center physicians, the designated data analyst 
for the Diabetes Team collected retrospective data between 7/1/2015 and 3/31/2016.  The data 
were related to information regarding inpatients in the oncology units with an ICD-10 diagnosis 
description containing "neoplasm" and with BG levels ≥200 mg/dl, with and without a Diabetes 
Team consult, as seen in Table 1 below.  The results revealed that over 50% of the 405 total 
patients that met sample criteria experienced BG readings reaching levels that were ≥300 mg/dl.  
In addition, there was a notable difference between the number of patients experiencing 
hyperglycemia without a Diabetes Team consult as compared to those who had one.  
Table 1  
BG Levels in Relation to Diabetes Team Consults on the Oncology Units 
Consult BG 
200-299 
BG 
300-399 
BG 
≥ 400 
Grand 
Total 
Yes 7 7 2 16 
No 194 151 44 289 
Total 201 158 46 405 
 
Another set of retrospective data was collected using information about patients who 
were admitted or transferred to the oncology units and were discharged between 1/1/2016 and 
8/31/2016.  These patients were also assigned an ICD-10 diagnosis containing “neoplasm” and 
medication orders for GCs, as seen in Table 2 below.  Variables collected included whether these 
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patients had orders for BGM, insulin therapy, and a Diabetes Team consult.  Of the 527 patients 
meeting the above criteria, 53% of the patients did not have orders for BGM, 70% did not have 
insulin orders, and 96% did not have a Diabetes Team consult.  Only 4% of the patients had the 
triple combination of orders for glucose checks, insulin therapy, and a Diabetes Team consult.   
Table 2 
BGM Orders, Insulin Orders, and Diabetes Team Consults on the Oncology Units 
Response 
BGM 
Orders 
Insulin 
Orders 
Diabetes Team 
Consults 
Yes 249 158 23 
No 278 369 504 
Totals 527 527 527 
 
The data results from both Table 1 and Table 2 reflect variability in care delivery, 
suboptimal monitoring and glycemic control, a gap in the timeliness of management, as well as 
the under-utilization of a valuable resource - the Diabetes Team.  Delays in treatment remain one 
of the top ten sentinel events in the nation, as recorded by The Joint Commission (TJC) (2016).   
Conceptual Framework 
The Iowa model by Titler et al. (2001) is a seven-step guide for translating evidence into 
practice.  The model places an emphasis on the importance of considering not only literature 
research but also other types of evidence in clinical decision-making (e.g., expert opinions, case 
reports, scientific principles, and theories), as seen in Appendix A.  The first step involves the 
identification of problem- or knowledge-focused triggers.  These triggers act as a catalyst for 
registered nurses (RNs) to evaluate current practices and question whether patient care could be 
enhanced based on empirical evidence (Hall & Roussel, 2014).  A unique feature of the Iowa 
model is that the issue of focus must be deemed a priority for the organization based on key 
factors such as the magnitude of the problem, its fit with the strategic goals of the organization, 
the number of people interested in the topic, the level of interdisciplinary support, cost 
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implications, and the potential barriers to change (Titler et al., 2001).  This is a pivotal piece in 
making successful progress to the second step of recruiting support and, in turn, formulating an 
interdisciplinary team likely comprised of all interested stakeholders (Doody & Doody, 2011). 
The third and fourth steps involve the retrieval, careful critique, and synthesis of relevant 
literature that support the change in clinical practice.  It is critical to determine whether or not 
sufficient data exists to validate the quality to guide the practice change.  Titler et al. (2001) 
recommended a group approach in order to: 1) Distribute the workload, 2) Increase 
understanding of the change, 3) Place accountability on all members, and 4) Create a learning 
environment for novices to gain practice with literature critique and application into practice.  
Incorporating other types of evidence or conducting a research study are two strategies to 
supplement the literature that has been collected to help the team develop the patient-centered 
EB practice change (Doody & Doody, 2011; Titler et al., 2001).    
The fifth step details the development of the practice change, with careful consideration 
of the implementation process to gauge its level of feasibility and effectiveness.  This stage of 
practice change development involves guideline establishment based on findings from the 
synthesized evidence, designation of the intervention outcomes, baseline data collection, and 
creation of an evaluation plan (Titler et al., 2001).  This stage lays the foundation for the sixth 
step of implementing the practice change.   
Once the practice change has been implemented, the seventh and final step encompasses 
the monitoring and analyzing of the structure, process, and outcome data.  This final evaluation 
stage is important to provide insight into the impact that the change in practice has made to 
patient care through comparison of baseline and post-implementation data (Titler et al., 2001).  
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Literature Critique and Synthesis 
An electronic search was completed using PubMed and CINAHL databases.  Search 
terms included glucocorticoids, steroids, hyperglycemia, cancer, oncology, inpatient, 
hospitalized, treatment, management, protocol, and guideline, which yielded a total of 104 
articles.  For the purpose of this review, twenty-one articles have been synthesized on the basis 
of exclusion criteria that included pediatric populations, non-English language publications, and 
articles published over six years ago.  
Mosby’s Quality of Evidence (Melnyk, 2004) was used to grade the level of evidence as 
represented in Table 3, with an “Other” category that includes quality performance improvement 
and review of the literature.   
The Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument was 
used for further evaluation of the two clinical practice guidelines (CPGs) included in the Level 
VII evidence, as seen in Table 4 below.  The AGREE II instrument consists of 23 key items 
organized within six domains followed by an overall quality assessment score of the guideline.  
The six different domains were designed to assess the methodological rigor and transparency in 
which the CPG was developed (Brouwers et al., 2013).  The domains include: 1) Scope and 
purpose, 2) Stakeholder involvement, 3) Rigor of development, 4) Clarity of presentation, 5) 
Applicability, and 6) Editorial independence.   Each domain includes a set of items that are rated 
on a 7-point scale (1– strongly disagree to 7–strongly agree) and subsequently calculated for a 
domain score.  The overall quality assessment score is also rated on a 7-point scale (1– lowest 
possible quality to 7–highest possible quality). 
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Table 3 
Number of Synthesized Articles According to Mosby’s Level of Evidence 
Level of 
evidence 
Description Number of 
articles 
I Meta-analysis 0 
II Experimental design/randomized control trial 1 
III Quasi-experimental design 0 
IV Case-controlled, cohort studies, longitudinal studies 10 
V Correlation studies 0 
VI Descriptive studies including surveys, cross-sectional 
design, developmental design, and qualitative studies 
3 
VII Authority opinion or expert committee reports 2 
Other Performance improvement, review of literature 5 
Note.  Descriptions of level of evidence adapted from the Mosby’s Quality of Evidence featured 
in “Integrating levels of evidence into clinical decision making,” by B.M. Melnyk, 2004, 
Pediatric Nursing, 30 (4), 323-325. 
 
Table 4: 
 Clinical Practice Guideline AGREE II Scores 
Reference Domain score Overall quality 
assessment score 
Roberts, James, & Dhatariya, 2014 86% 6 
 
Umpierrez et al., 2012 91% 6 
 
Note.  The AGREE II Tool can be found at http://www.agreetrust.org 
 
All of the reviewed articles feature the topic of hyperglycemia or GCIH, with the 
majority of the articles concentrating on the hospitalized adult oncology population receiving 
GCs concurrently with chemotherapy.  The themes from the literature that were specifically 
recognized for this DNP project include: 1) GCIH prevalence, 2) Definition of hyperglycemia, 3) 
Effects of hyperglycemia on patient outcomes, 4) BGM protocols for GCIH, and 5) Treatment 
for GCIH.   
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Prevalence of GCIH 
The prevalence rate of GCIH varied among the literature, ranging from 22.1% to 86%.  
Although it is expected that sample sizes and duration of BGM will differ among studies, the 
specificity of the inclusion and exclusion characteristics of the sample population appeared to 
have the most notable impact on the prevalence rate, particularly to patients without a prior 
history of DM.  Certain studies excluded patients with pre-existing DM, as well as those with a 
history of previously elevated BG (Fong & Cheung, 2013; Jeong et al., 2016; Pilkey, Streeter, 
Beel, Hiebert, & Li, 2012).  Other studies excluded patients who were already on medications 
that caused secondary hyperglycemia (Fong & Cheung, 2013; Gonzalez-Gonzalez et al., 2013).  
These criteria were enforced in an attempt to control for potential external factors that could 
concurrently contribute to the hyperglycemia and help to specifically evaluate the effects of GCs 
on glycemic levels.   
With regards to the literature that did not enforce the exclusion criteria, it is difficult to 
ascertain whether the patients from the associated study were truly experiencing GCIH.  For 
instance, in the prospective cohort study by Harris et al. (2013, Level IV), hyperglycemia was 
detected in a total of 58.9% of the sample, which included both non-DM and DM patients.  In 
contrast, a correlation pilot study that evaluated hyperglycemia specifically in non-DM 
chemotherapy-treated cancer patients receiving antiemetic dexamethasone therapy, showed a 
GCIH prevalence rate of 22.1% (Jeong et al., 2016, Level IV).  Interestingly, in a prospective 
case-controlled study, which controlled for a non-DM sample, 86% of patients who were 
administered high-dose steroids experienced at least one episode of hyperglycemia (Fong & 
Cheung, 2013, Level IV).  Nonetheless, despite varying sample populations, the literature 
confirms the prevalence of GCIH in patients both with and without a history of DM. 
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Definition of Hyperglycemia   
Hyperglycemia was most frequently deemed as fasting levels or pre-prandial BG levels 
>140-144 mg/dl, or a random or two-hour postprandial BG level >180 mg/dl (Brady et al., 2014, 
Level Other; Fong & Cheung, 2013, Level IV; Gerards, Tervaert, Hoekstra, Vriesendorp, & 
Gerdes, 2015, Level VI; Harris et al., 2015, Level IV; Jung et al., 2014, Level IV; Lansang & 
Hustak, 2011, Level VII; Perez et al., 2014, Level Other; Roberts, James, & Dhatariya, 2014, 
Level VII; Seheult et al., 2015, Level VII).  The American Diabetes Association and the 
Endocrine Society both define inpatient hyperglycemia as any BG value ≥140 mg/dl (Umpierrez 
et al., 2012, Level VII).  Therefore, the variance in hyperglycemia definitions among the 
literature could be attributed to the differing characteristics of the sample populations.     
More stringent definitions of hyperglycemia included fasting BG levels >100-110 mg/dl.  
It is probable that the use of this hyperglycemia definition in the Level IV study by Gonzalez-
Gonzalez et al. (2013) was due to the acuity level of the sample population, which involved non-
critically ill adult patients receiving GCs who likely did not have a history of DM or 
hyperglycemia at baseline.  The aim of the Level IV study by Fuji et al. (2009) focused on the 
benefits of intensive glucose control after allogeneic hematopoietic stem cell transplantation and 
thus, glycemic goals were of a lower threshold.  In contrast, less stringent hyperglycemia 
definitions included BG levels >200-215 mg/dl.  Examples of this definition classification were 
evident in the Level IV study by Pilkey et al. (2012), where the sample population involved 
palliative care patients who would not benefit from strict glycemic control.  Overall, the presence 
of conflicting hyperglycemia definitions suggests the under-treatment of hyperglycemia in 
hospitalized patients nationwide.   
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Effects of Hyperglycemia on Clinical Patient Outcomes 
It has been well established in the literature that hyperglycemia contributes to poor 
clinical patient outcomes.  A literature review that included 124 articles from over the time span 
from 1976 to 2014 (Corsino et al., 2014, Level Other), along with a Grade 6 quality CPG 
(Umpierrez et al., 2012, Level VII), emphasizes that even transient hyperglycemia can be linked 
to increased risks of mortality and incidences of infection, deleterious effects on the immune 
system, prolonged hospital stays, higher admission rates to an intensive care unit, and increased 
disability after discharge that warrants greater needs for transitional or nursing home care.   
A prospective observational cohort study by Koskela et al. (2014, Level IV) monitored 
the correlation between mortality and the occurrence of postprandial hyperglycemia in 153 
consecutive hospitalized patients admitted for mild to moderate community-acquired pneumonia.  
At the end of the five-year follow-up, the patients in the sample population who were admitted 
without prior DM diagnosis, but who acquired postprandial hyperglycemia within the first 24 
hours of their hospitalization, had a 37% mortality rate, as compared to patients without a DM 
diagnosis and without postprandial hyperglycemia.   
Similarly, another retrospective cohort study by Buehler et al. (2015, Level IV) evaluated 
the effects of hyperglycemia in 2,451 patients, with and without a history of DM, who underwent 
gastrointestinal surgery.  The differences in mean calculated costs of care in patients with no 
diabetic history and normoglycemia, no diabetic history and hyperglycemia, and diabetics, were 
illustrated, as seen in Table 5 below.  The calculated costs in relation to Hawaii hospitals were 
retrieved (Kaiser Family Foundation, 2016; Rizzo, 2013) and included to better evaluate the 
differences.  
It is interesting to note that even without a previous history of DM, hyperglycemia can be 
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costly, with greater risks of complications, length of stay, and overall hospitalization costs.  In 
comparison to the patients with normoglycemia, the 64.3% of patients who experienced 
hyperglycemia had a higher number of complications, longer hospital stays, more readmissions 
within 30 days, and higher hospitalization costs.    
Table 5 
Comparison of Mean Calculated Hospital Costs Based on Glycemic Status 
 A) No-DM, 
normoglycemic,  
N (per article) 
B) No-DM, 
hyperglycemic, 
N (per article) 
C) DM  
N (per article) 
Calculated 
Hawaii cost 
Complications: 
LOS days 5  9 9  
 
$2,157 per day 
A = $10,785 
B =  $19,413 
C =  $19,413 
Readmission in  
30 days 
49  193 85  $11,200 per case 
A=548,800 
B=$2,161,600 
C=952,000 
Acute MI 1 22 10 $13,200 per case 
A = $13,200 
B = $290.400 
C = $132,000 
Wound infection 19 129 53 $3,937 per case 
A = $74, 803 
B = $507,873 
C = $208,661  
Pneumonia 8 108 50 $13,000 per case 
A = $104,000 
B = $1,404,000 
C = $650,000 
Sepsis 1 5 3 $18,400 per case 
A = $18,400 
B = $92,000 
C = $55,200 
Total hospitalization 
costs 
$20,273 $72,675 $79,545  
Note: *Calculated Hawaii costs are from 2013-2016 sources and may differ from current costs. 
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In recent years, there has been limited literature that explains the correlation of 
hyperglycemia and adverse outcomes specifically among oncology patients; however, the 
available data is consistent in reinforcing the significance of managing hyperglycemia to reduce 
negative outcomes.  A retrospective case-controlled study by Jung et al. (2014, Level IV) 
investigated the correlation between the incidence of hyperglycemia and the development of 
severe infection during the early period of initial chemotherapy in patients with newly diagnosed 
multiple myeloma.  An analysis of 155 patient records between November 2002 and February 
2013 revealed that the patients who developed severe infections were part of the overt 
hyperglycemia group, experiencing BG levels above 200 mg/dl (Jung et al., 2014, Level IV).   
Similar results were noted in a retrospective cohort study by Fuji et al. (2009, Level IV) 
that involved recipients of allogeneic hematopoietic stem cell transplantation (HSCT) in patients 
with hematologic malignancies.  The study first examined the benefits of intensive glucose 
control (IGC) by monitoring BG levels every morning and up to four times a day, with glycemic 
correction with insulin as needed.  The study went on to evaluate the benefits of standard glucose 
control (SGC), which entailed no specific protocol aside from monitoring at least three times 
weekly to avoid severe hyperglycemia.  The study found that the incidence of documented 
infections – particularly bacteremia - within 100 days of HSCT was significantly lower in the 
IGC group compared to the SGC group, with a positive correlation between infection and 
hyperglycemic rates (Fuji et al., 2009, Level IV).   
Finally, a study by Weiser et al. (2004, Level IV) was conducted to determine the 
prevalence of hyperglycemia during induction chemotherapy for acute lymphocytic leukemia 
using a regimen comprised of dexamethasone and to determine the effect of hyperglycemia on 
survival, duration of disease remission, and treatment-related complications.  Of the 278 patients 
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included in the study, 103 (37%) experienced GCIH with BG levels >200 during induction 
chemotherapy, and only 20 of those patients (7%) had a previous diagnosis of DM.  Patients with 
hyperglycemia had a shorter median complete remission duration (24 months vs. 52 months) and 
a shorter median survival (29 months vs. 88 months) compared with patients without 
hyperglycemia.  Those patients who experienced hyperglycemia were also more likely to 
develop sepsis (16.5% vs. 8%) compared with patients without hyperglycemia. 
Although these studies demonstrate sufficient internal validity, there are threats to 
external validity, as the studies focused specifically on multiple myeloma, recipients of HSCT, 
and ALL.  Additional prospective studies are needed to assess whether enhanced glycemic 
control can improve outcomes in a variety of oncology diagnoses.  Overall, the importance of the 
need to control hyperglycemia, both promptly and adequately, continues to be emphasized. 
BGM Protocols for GCIH 
Despite the evidence, which emphasizes the significance of hyperglycemia on patient 
outcomes, the literature reveals that BGM is often overlooked in hospitalized patients, especially 
in patients without prior DM history.  For example, a prevalence study by Narwani et al. (2014, 
Level VI) was conducted over two consecutive days on patients receiving GCs for various 
indications, with 10% of the patient cohort receiving GCs for oncologic reasons.  Results showed 
that only 25 of the total 120 patients (20.8%) received routine BGM during their hospitalization.  
Patients with pre-existing DM were more likely to have BGM compared to those without DM.   
This study by Narwani et al. (2014, Level VI) primarily focused on process prevalence, 
and thus, was met with the limitation of whether BG levels and patient outcomes were affected 
by the lack of monitoring.  It is also difficult to discern whether the exact reason for the absence 
of monitoring was due to a lack of knowledge by providers to place BGM orders, failure of 
   
20 
BGM to be initiated by staff, or the lack of perceived need of BGM by providers based on the 
patients’ characteristics.  The inconsistency in BGM reveals a possible lapse in knowledge 
regarding the deleterious effects of GCIH and the significance of BGM.      
A factorial survey by Gerards et al. (2015, Level VI) involving 106 clinicians from 31 
different hospitals evaluated the current practice of screening for GCIH, the intention to start 
therapy, and the therapy of choice.  Results showed that clinicians were more likely to order BG 
testing for GCIH for patients with a pre-existing DM diagnosis and patients with a history of 
random hyperglycemia prior to initiation of GCs.  Over half of the clinicians indicated their 
preference for more lenient glucose goals than the glycemic guidelines set for non-critically ill 
patients, with a lesser overall tendency to order BGM, as compared to clinicians who aimed at 
stricter BG level goals.  An interesting observation detailed the notion that the more experienced 
physicians typically chose the more lenient glycemic goals, while the resident physicians opted 
for stricter glycemic goals.  This could suggest that there is a greater concern for hypoglycemia, 
rather than hyperglycemia, and may even hint towards an inverse relationship between years of 
experience and adherence to guidelines.  The responses could also imply the tendency of 
physicians to manage more conservatively, potentially relying on endocrinologists to cover 
glycemic management.   
This study by Gerards et al. (2015, Level VI) was limited by the lack of representation of 
providers from different specialties as the clinicians included internists and pulmonologists.  
Additionally, there was a low response rate, which potentially gave rise to biased responses as 
responders may have chosen to participate due to interest in the topic of GCIH.      
Despite the inconsistent frequency of BGM, as well as the differing clinician views 
regarding orders for BGM, all of the data reviewed support the necessity of BGM with GC 
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therapy.  The literature consistently recommended that BGM take place at least once a day, 
preferably two hours after lunch or before dinner, for patients without DM history because GCs 
mainly affect postprandial glycemic levels.  The frequency of BG checks could be increased to a 
maximum of four times a day in the presence of persistent hyperglycemia >180 mg/dl within a 
24-to 48-hour duration, with subsequent initiation of treatment (Fong & Cheung, 2013; Lansang 
& Hustak, 2011; Perez et al., 2014; Roberts et al., 2014; Umpierrez et al., 2012).  One CPG 
advised that when BG readings remain <140 mg/dl without insulin therapy for at least 24–48 
hours, BGM can be discontinued, while another CPG suggested discontinuation of BGM when 
BG readings remain <180 mg/dl (Roberts et al., 2014; Umpierrez et al., 2012).  The CPG by 
Umpierrez et al. (2012) provided a reference list of their supporting evidence and is backed by 
the Endocrine Society and the American Diabetes and Heart Associations; the CPG by Roberts et 
al. (2014), however, failed to provide a reference list and is based out of the United Kingdom.     
Treatment for GCIH 
There is a lack of consensus about the most effective GCIH management method for 
hospitalized patients with cancer.  The Grade 6 CPG by Umpierrez et al. (2012) suggested that 
basal-bolus insulin (BBI) with a starting dosage of 0.3 to 0.5 U/kg/d should be initiated for 
management of GCIH.  A recommendation was also made that continuous insulin infusion was 
to be administered in cases of persistent hyperglycemia that fail to respond to the BBI treatment 
(Umpierrez et al., 2012).  A retrospective case-controlled study (Gosmanov, Goorha, Stelts, 
Peng, & Umpierrez, 2013, Level IV) supports the BBI regimen of detemir and aspart as effective 
and safe options for the management of GCIH in DM patients with hematologic malignancies 
receiving dexamethasone.  
In contrast to these two studies, a randomized prospective clinical trial (Vu et al., 2012, 
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Level II) showed that the intensive BBI therapy did not improve the outcomes in hyperglycemic 
patients with acute lymphoblastic leukemia, Burkitt lymphoma, and lymphoblastic lymphoma for 
those patients who underwent hyper-CVAD chemotherapy, which includes high-dose 
dexamethasone or methylprednisolone.  This study compared BBI therapy of glargine and aspart 
with conventional care, which comprised non-standardized glycemic control managed at the 
discretion of the attending physician.  Although results may have conflicted based on differing 
insulin therapies and oncology diagnoses, an emphasis was made on the need for insulin therapy 
for GCIH management.  
Limitations 
Aside from those previously mentioned, each publication included minor limitations.  
Sample characteristics provided the most frequent limitations, mainly involving a small sample 
size, a focus on specific oncology populations, a lack of consideration for comorbidities, and an 
inconsistency in the inclusion of patients with preexisting DM.  These characteristics threatened 
both the internal and external validity of the data.  Although there was a trend noted by the type 
of GCs prescribed concurrently with chemotherapy – dexamethasone – not all studies controlled 
for the various doses and route of medication.  Without the aforementioned factors controlled 
for, BG levels may have been affected differently, leading to variability in results and subsequent 
treatment.  
Summary of Literature Review 
Despite its established prevalence, the impact of GCIH on clinical outcomes in oncologic 
patients is limited.  Additional prospective studies regarding the benefits of BGM and optimal 
GCIH management in oncology patients are warranted.  The majority of the data reviewed – ten 
of 21 articles – was derived from Level IV data, with only one Level II study, three Level VI, 
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two Level VII, and five systematic and literature reviews. Overall, the publications are deemed 
to be of fair to good internal validity.  The synthesized articles demonstrated the prevalence of 
GCIH, the need for a consensus and overall awareness of the definition of hyperglycemia, the 
adverse effects resulting from GCIH that highlight the importance of its management, and the 
inconsistencies of BGM and GCIH treatment. 
Innovation/Objectives 
Evidence has emphasized the short- and long-term deleterious effects of both transient 
and prolonged hyperglycemia and has highlighted the importance of BGM as a paramount 
precursor to therapeutic interventions for GCIH.  The reviewed literature revealed a gap in the 
perceived significance and proper management of GCIH by healthcare providers.  Yet, recent 
retrospective organizational data from two oncology units highlights variability in GCIH 
management, suboptimal monitoring and glycemic control, and a gap in the timeliness of 
therapy, with an underuse of a valuable resource - the Diabetes Team.  A practice change was 
therefore warranted.   
The most appropriate EB strategy was the implementation of a standardized protocol for 
the assessment and management of GCIH.  Protocols are helpful guiding tools for providers to 
recommend appropriate EB clinical treatment modalities in different diagnoses or patient care 
scenarios.  The basis for EB protocols stems from an extensive literature review, with the 
integration of clinical practice expertise by key stakeholders in the specified practice area (Hall 
& Roussel, 2014).  
The goal of the GCIH protocol was to initiate early BGM and insulin therapy for patients 
with hematologic malignancies who were prescribed a treatment plan that included GCs in the 
inpatient oncology units.  Although it is inevitable that hyperglycemia will result from GC 
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therapy, the implementation of an EB protocol was intended to promote patient safety by 
providing RNs with the knowledge and tools for prompt GCIH recognition and treatment.  This 
protocol aimed to standardize GCIH assessment, enabling early detection of GCIH and 
decreasing the delay in the initiation of appropriate management.  Prompt and proactive 
management was expected to reduce the incidence of uncontrolled GCIH and prevent adverse 
outcomes that may result from GCIH.   
The protocol was intended to be RN-driven, as one of the goals of this project was to 
improve the timeliness of GCIH management.  According to TJC International (2013), one of the 
main advantages of RN-driven protocols is greater decision-making power for RNs.  This 
impacts the timeliness of patient care and, subsequently, gives rise to positive effects on safety, 
patient outcomes, and patient satisfaction.  An algorithm was provided to guide staff in the 
management of inpatients who meet GCIH levels.    
In the case of GCIH assessment and management, the plan was to change the process, 
which involved an inconsistent practice of ordering BGM and insulin when GCs were ordered.  
As part of the protocol, a BPA (see Appendix B) was initiated to provide an alert that informed 
the end-user that the patient is on a prescribed glucocorticoid therapy regimen and is at risk for 
GCIH.  The same alert allowed the provider to instantly order BGM, sliding scale insulin (SSI), 
and/or a Diabetes Team consult.  For the RNs, the alert instructed them to obtain orders from the 
attending physician.  The BPA was expected to help minimize the time between initiating GCs 
and detecting and addressing the resulting hyperglycemia – thereby reducing prolonged 
untreated GCIH.  The BPA was also intended to save time for the providers, as all the orders 
were made available for selection in one screen. 
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Because GCs classically play a role in causing exaggerated postprandial hyperglycemia 
and have a far less effect on fasting glucose, random BG levels are the preferred measurement 
(Harris et al., 2013; Lansang & Hustak, 2011).  However, as the aim of the project was to 
monitor trends to promptly identify GCIH and manage glycemic levels, BGM ordered through 
the BPA was scheduled four times a day – before each of three meals (AC) and at bedtime (HS) 
– for all oncology inpatients with hematologic malignancies who are on a treatment plan with 
GCs.  This schedule also minimized confusion for the RN staff, as it is the typical BGM schedule 
for inpatients with orders for BG checks.   
Due to its immediate onset, efficacy, and easy titration, insulin therapy is the most 
optimal and preferred treatment method (Brady et al., 2014; Gosmanov et al., 2013; Lansang & 
Hustak, 2011; Perez et al., 2014; Pilkey et al., 2012).  As the objective of the protocol was to 
reduce the incidence of uncontrolled hyperglycemia, a low-dose regular sliding scale insulin 
(SSI) was the featured insulin therapy, within the order set to address BG levels >200 mg/dl.  A 
low-dose regular SSI was chosen, as there is limited evidence that tight glycemic control benefits 
patients being treated for cancer.  This insulin regimen was also chosen to reduce the potential 
for hypoglycemia.   
Findings support the fact that hyperglycemia has a rapid onset, typically developing 
within one to two days of GC therapy initiation (Fong & Cheung, 2013). For the first 48 hours, 
BGM will likely identify the majority of those patients with GCIH and thus, management should 
be initiated.  Likewise, management could be discontinued if elevated levels do not occur within 
this timeframe (Roberts et al., 2014; Umpierrez et al., 2012).  Therefore, an algorithm was 
developed as part of the protocol (see Appendix C) to reflect this evidence and provide 
management guidance for the staff.  The algorithm also underwent appraisals by key 
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organizational groups: The Diabetes Care Committee (DCC), the oncology unit nursing staff, 
and the Department of Oncology Committee (DOC).  
Summary 
The magnitude of the impact of GCIH on patient outcomes should no longer be 
overlooked.  The inconsistencies in BGM, as well as the prevalence of hyperglycemia in patients 
receiving GCs highlight the potential delays in treatment of GCIH.  The resulting negative 
effects of GCIH on the patients are evident in the literature.  The reviewed literature, as well as 
the data collected at the organization, support the need for an EB protocol targeted at the early 
detection and prompt management of GCIH.   
   
27 
CHAPTER 3: METHODS 
Introduction 
In accordance with the Iowa Model (Titler et al., 2001), steps 1-4 have been completed, 
as discussed in Chapter 2.  The three remaining steps in the Iowa Model are as follows:  1) The 
development of a practice change, 2) Implementation, and 3) Evaluation.  The purpose of this 
chapter is to provide an in-depth explanation of these final three steps, covering details of the 
action plans in each stage, including the description of the practice change, definitions, the 
sampling plan, the data collection procedures, and plans for evaluation.  Prior to providing this 
explanation, it will be noteworthy to first revisit the driving force behind this DNP project by 
reviewing the objectives of the project through the patient population, intervention, comparison 
intervention, and outcome (PICO) format, and the purpose statement. 
Objectives 
P-Patient Population   
The target population was the adult oncology patients with hematologic malignancies 
who were on an active treatment plan that included GCs.  These patients were admitted or 
transferred to and discharged from either of the two 24-bed medical/surgical/telemetry inpatient 
oncology units at the tertiary care center. 
I-Intervention 
The intervention was the implementation of an EB protocol involving an algorithm that 
guided staff in the assessment and management of GCIH.  This protocol also included a 
corresponding BPA that linked the GC order with an alert that allowed the provider to order 
BGM, SSI, and a Diabetes Team consult.  
 
   
28 
C-Comparison Intervention 
The intervention for this project was compared to current practice, which involved no 
established GCIH protocol.  
O-Outcome 
The outcome goal for this project was a 25% improvement in the baseline rates of BGM, 
insulin orders, consults to the Diabetes Team, and incidences of uncontrolled hyperglycemia 
(>180 mg/dl).  This would reflect an overall reduction in the delay of detection and management 
of GCIH. 
Purpose 
The purpose of developing and implementing an EB protocol was to standardize the 
BGM and SSI, in order to promote early GCIH detection, as well as initiate appropriate 
management strategies to reduce the rates of uncontrolled hyperglycemic episodes experienced 
by the inpatient hematologic malignancy population receiving GCs.   
Practice Change Description 
There was no set protocol in the inpatient setting for the assessment and management of 
GCIH.  An entirely separate order for BGM, an insulin regimen, or a Diabetes Team consult 
from the GC order would need to be placed by the provider, and only if they are concerned about 
the risk of GCIH.  The background data featured in Table 1 and Table 2 supports how this order 
system has led to inconsistencies in care, as certain patients may have not been appropriately 
assessed for GCIH.  The process is detailed as follows:  
1.   Patient with a hematologic malignancy diagnosis is admitted or transferred to the 
inpatient oncology unit. 
2.   The oncologist places orders for a treatment plan that includes GC therapy. 
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3.   The oncologist may or may not place separate orders for BGM, insulin orders, or a 
Diabetes Team consult. 
a)   If BGM is ordered, RN staff performs BGM, but may or may not notify the 
provider of elevated BG levels. 
b)   If insulin is ordered, there is no standard type of therapy.  
c)   Diabetes Team is rarely consulted. 
The Practice Change  
The proposed GCIH assessment and management protocol entailed a BPA (see Appendix 
B) that appeared for the RN and provider when the targeted patient chart was opened.  Criteria 
for the targeted patient charts included patients on the two oncology units with a diagnosis of a 
hematologic malignancy, with an active treatment plan that included GCs, and with no BGM 
orders.  For patients who do not meet all three parts of this criteria, the BPA would not be 
activated.   
When the BPA appeared for the RN, the RN was instructed to select the “RN to obtain 
orders from Attending Physician” option, which defaulted all options to “Do Not Order,” and 
call the provider for the orders.  This also prompted the BPA to stop firing for the following 
eight hours.  Thereafter, the RN or provider would place the corresponding orders.  When the 
BPA fired for the provider, the provider could place the orders themselves.  
If BGM or SSI orders were placed by either the RN or provider, the BPA firing stopped.  
However, if the provider did not want any orders, the “Not applicable” selection would be 
chosen the next time the BPA fired, causing the BPA to not fire for the next 999 hours.  A 
Diabetes Team Consultation order could also be selected at any time, however, it was 
recommended to be placed only when BG levels remained greater than 180 mg/dl for at least 24 
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hours, despite treatment with SSI orders.   
The corresponding algorithm, as seen in Appendix C, provides guidance for the staff 
regarding GCIH management.  It indicates when and who to escalate care to, based on 
established BG level readings.  In the event that all of the patient’s BG results remain ≤140 
mg/dl for a consecutive 48-hour period of BGM and without the use of insulin therapy, BGM 
can be discontinued.  The RN would need to obtain this discontinuation order from the provider.  
Resuming BGM would be considered if the patient developed symptoms of hyperglycemia, if 
morning serum BG levels were noted as elevated (>140 mg/dl) in the basic metabolic panel 
results, or if GC dosing increased.  
Conversely, if the patient had an AC BG level ≥140 mg/dl or HS BG level ≥180 mg/dl 
for at least two readings within the first 24 hours of BG monitoring, the patient would meet the 
criteria of GCIH diagnosis.  At this time, the RNs would continue BGM and administration of 
SSI, while keeping close attention to BG levels.  If, despite the SSI therapy, BG levels 
consistently remained ≥180 mg/dl for 24 hours, the Diabetes Team should be consulted to 
enhance GCIH management.  Overall, the algorithm provides the needed guidance to 
appropriately direct care in regards to GCIH in a timely and standardized manner.   
Characteristics of the Innovation  
Rogers (2003) explains that the perception of the characteristics of innovation by 
prospective adopters helps to determine their level of willingness and involvement, as reflected 
by the rate of adoption.  Accordingly, the potential of success in adopting the practice change 
will largely be determined if the following five characteristics are satisfactorily addressed: 1) 
Relative advantage, 2) Compatibility, 3) Complexity, 4) Trialability, and 5) Observability.  The 
following sections will review these five innovation attributes in relation to the GCIH assessment 
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and management protocol. 
Relative advantage.  For the chief users, the oncologists and the RN staff, a key relative 
advantage of this practice change is convenience.  The protocol was intended to save extra steps 
– and thus, time - for oncologists when placing orders.  These conveniences would expectantly 
lead to prompt management of the GCIH and help to mitigate its negative outcomes.   
The protocol was designed to be RN-driven, which aimed to empower RNs to properly 
assess BG levels and collaborate with the providers to obtain orders when necessary.  This could 
be viewed as another opportune, timesaving feature of the protocol for the oncologists.  
According to TJC International (2013), one of the main advantages of RN-driven protocols is 
greater decision-making power for RNs.  This impacts the timeliness of patient care and, 
subsequently, gives rise to positive effects on safety, patient outcomes, and patient satisfaction. 
In regard to the relative advantage for patients, a feature of the protocol involved 
discontinuation of BGM when all BG levels remain ≤140 mg/dl for 48 hours without insulin 
therapy.  The purpose of this distinction was to promote patient satisfaction, as patients would 
more than likely prefer to not have their fingers unnecessarily punctured up to four times per 
day.  Ultimately, the relative advantage for patients would be the potential decrease in the 
number of uncontrolled hyperglycemic episodes (≥180 mg/dl), as well as ALOS, primarily 
through a more efficient method of glycemic control.  
Compatibility.  In examining the compatibility aspect of the project, the focus was on 
the needs of the adopters.  The physicians at the Cancer Center initially raised the issue of GCIH 
after noting an increasing trend in hyperglycemia within their oncology outpatients receiving 
chemotherapy with GCs as part of their treatment.  In March 2016, the Cancer Center reached 
out to the inpatient Diabetes Team and a partnering Cancer Center to inquire about their use of 
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management guidelines specific to GCIH.  This inquiry revealed that GCIH protocols had not 
been established with either group.  With further investigation into the inpatient oncology 
population that received GCs, data collection revealed variability in care delivery, the lack of 
timely management, and suboptimal glycemic control.  The variability was evidenced by the 
underuse of the Diabetes Team, inconsistencies in BGM orders, and BG levels as high as the 400 
mg/dl range.  Therefore, the protocol was intended to meet multiple needs for the oncology 
department.  
Delays in treatment remain one of the top 10 sentinel events in the nation, as recorded by 
TJC (The Joint Commission, 2016).  The Endocrine Society, as well as TJC, advise GCIH 
assessment and management.  The protocol would assist to meet organizational goals and to be 
in alliance with standards outlined by the Endocrine Society and the TJC. 
Finally, in order to maintain their accreditation, the Oncology group must meet the 
Commission on Cancer Standard 1.5 Clinical each calendar year.  This standard involves the 
cancer committee establishing, implementing, and monitoring at least one clinical and one 
programmatic goal for endeavors related to cancer care.  This practice change had been approved 
by the committee to help fulfill this standard.  
Complexity.  The degree of complexity for this practice change was projected to be low 
for the providers, as the BGM and SSI orders would be updated to link with the GC orders 
through the BPA.  Therefore, the oncologists would resume their usual process of ordering 
treatment plans, without needing to place any additional effort on simultaneously addressing 
GCIH.   
The complexity level for the RNs was aimed to, likewise, be low, as the skills of BGM 
and insulin administration are considered routine nursing tasks.  Furthermore, at this practice 
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setting, RNs can delegate BGM to nursing assistants, who are competent in performing this task 
as well.  The competencies to review lab results and subsequently report and initiate care when 
necessary are also established practices for the RNs.  This protocol would merely provide 
guidance to appropriately direct care in a timely and standardized manner.  However, one 
complex aspect may have involved the shift in mindset towards recognition and interpretation of 
BG levels before proceeding to the next step in the algorithm.    
Trialability.  In considering trialability of the practice change, the implementation of the 
protocol was planned for a short trial period of four months and piloted on focused diagnoses, 
rather than all oncologic inpatients at once.  As collectively suggested by the oncologists during 
the DOC and Cancer Steering Committee (CSC) meetings, a pilot should focus on hematologic 
malignancies, as patients of these diagnoses are prescribed the highest doses of GCs.  With 
ongoing evaluation, modifications to the protocol could easily be achieved in preparation for the 
next steps of implementation, and involve all oncologic inpatients receiving GCs.  Moreover, 
these initial achievements would ultimately substantiate extending the protocol to the whole 
organization for all types of patients receiving GC therapy.  Equally, if the protocol proved to 
completely fail in functioning with the staff’s workflow, was met with disapproval by patients, or 
exhibited worsening results, it could and would easily be revised or discontinued.  
Observability.  The protocol was expected to project observability for the adopters 
through the increase in BGM and insulin orders in their patients, with an ensuing reduction in the 
frequency of uncontrolled hyperglycemia levels.  The algorithm was displayed in various areas 
of the unit for easy access and increased visibility.  As the protocol was projected to 
progressively become adopted and immersed in the staff’s routine, it was anticipated that peer 
accountability would ensue to ensure prompt detection of GCIH and that the proper steps are 
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taken to manage the patients’ BG levels.  
Definitions 
While conceptual definitions describe what a concept means, operational definitions 
specifically define how the concept is measured using terms that can be counted and 
categorically described (O’Brien, Trindell, Tarpley, & Wiberg, 2014).  This section addresses the 
operational definitions of the impact and process evaluations.  Conceptual and operational 
definitions are listed in Table 6.   
 
Table 6 
 
Conceptual and Operational Definitions of the Impact and Process Evaluation Outcomes for 
the Baseline and Intervention 
Term Conceptual Operational 
Impact evaluation  
Uncontrolled 
hyperglycemia 
episode 
Occurrence of abnormally 
high blood glucose (BG) 
level 
Occurrence of BG level ≥180 mg/dl 
Average length of 
stay (ALOS) 
 
Average duration of a 
hospitalization, measured in 
days 
ALOS measured by days  
Process evaluation 
Blood glucose 
monitoring (BGM) 
orders  
 
A method of monitoring 
individual patterns of BG 
levels (American Diabetes 
Association, 2016) 
Provider orders for BGM four times a day: 
AC and HS  
*Exception: Any variation of BGM orders 
Insulin therapy 
orders 
 
A critical part of treatment 
for people diabetics to 
maintain BG levels within 
target range (Mayo Clinic, 
2016). 
Provider orders for regular (Humulin R) 
low-dose SSI, which starts insulin dosing 
at >200 mg/dl AC and HS  
*Exception:  Any variation of rapid- or 
short-acting insulin orders 
Diabetes Team 
consult orders 
 
A referral to a healthcare 
team specializing in 
diabetes care 
An order on the patient’s chart indicating 
consultation to the inpatient Diabetes 
Team has been placed 
Adherence 
 
The act, action, or quality 
of adhering (Merriam-
Webster, 2017). 
User adherence to the protocol is exhibited 
by the presence of BGM orders, insulin 
therapy orders, or Diabetes Team consults 
Note:  The operational definition of each baseline is the measurement taken before the 
intervention.   
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Impact evaluation 
The impact evaluation explores the relationship between the GCIH protocol and the 
overall uncontrolled hyperglycemia rates and ALOS days in the adult oncology inpatients with 
hematologic malignancies receiving GCs.  The operational definition for uncontrolled 
hyperglycemia episode is an occurrence of BG level ≥180 mg/dl.  The operational definition for 
ALOS is measured in days.  The ALOS is linked to the variable, Diabetes Team consults, that is 
being assessed of the population, as well as the highest BG level reading during the hospital stay.  
Process evaluation   
The process evaluation measures user adherence to the new protocol for the assessment 
and management of GCIH.  User adherence to the protocol is exhibited by the presence of BGM 
orders, insulin therapy orders, and Diabetes Team consults, as these three proxy measures are 
directly related to the correct use of the protocol.   
The operational definition for a BGM order is a provider order for BGM that takes place 
four times a day, AC and HS.  An exception would be any variation of BGM orders such as 
twice a day or every six hours.  A lack of BGM is considered as non-adherence to the protocol.   
The operational definition for insulin therapy orders is a provider order for regular 
(Humulin R) low-dose SSI, which starts insulin dosing at BG levels >200 mg/dl, AC and HS.  
An exception would be any variation of rapid- or short-acting insulin orders; otherwise, an 
absence of insulin therapy is considered as non-adherence to the protocol.   
The operational definition for a Diabetes Team consult is an order on the patient’s chart 
indicating that a consultation with the inpatient Diabetes Team has been placed.  The preferred 
scenario involves a Diabetes Team consult for eligible patients who experience persistent 
uncontrolled hyperglycemia, BG levels remaining greater than 180 mg/dl for at least 24 hours, 
   
36 
despite treatment with SSI orders.  A presence of a Diabetes Team consult would be an 
indication that the staff understands the proper use of the protocol.  However, in the event that 
users placed the consult even when the patient did not meet the aforementioned eligibility, these 
cases will still be considered as an indication of user adherence.  This exception was made to 
promote early consultation, an ideal option over late or no Diabetes Team consultation for these 
patients who are at risk for GCIH.  An absence of a Diabetes Team consult for patients who meet 
eligibility for consultation indicates user non-adherence.   
The Sampling Plan 
Setting 
Practice setting.  The GCIH assessment and management protocol was implemented on 
two inpatient oncology units at a large tertiary care center in Honolulu, Hawai’i.  Together, these 
units can accommodate a total of 48 patients of the medical/surgical/telemetry level of care, 
specializing in assisting those who have an oncologic history or admission diagnoses.  The total 
nursing staff for the two units is approximately 100 RNs, as well as 20 nursing assistants.  A 
multidisciplinary team is able to provide direct care for each patient.  This team typically 
includes: 1) Physicians from various specialties, 2) The nursing staff, who each member carries a 
3-5 patient workload during their shift - a number that varies based on acuity levels and staffing 
availability, and 3) Nursing Assistants.  Ancillary support for the oncology units includes the unit 
secretaries, a social worker, a case manager, an RD, the oncology pharmacists, and specialty care 
teams (i.e., diabetes, pain and palliative, wound care, etc.).  A nurse manager and a clinical 
operations manager oversee all of the unit staff.  All units within the organization practice a 
shared governance structure, with a unit council that serves as the communication liaison 
between staff and upper management.  
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Sample   
Sample size.  The sample size is intended to include all the patients who met the 
inclusion criteria of the evaluation.  This implementation intended to be a 100% sample.  
Inclusion criteria.   
Impact evaluation.  This evaluation focused on adult oncology patients with hematologic 
malignancy diagnosis of the medical/surgical or telemetry level of care.  These patients were 
admitted or transferred to and discharged from either of the inpatient oncology units, between 
September 1, 2017 to December 31, 2017, and who were prescribed an active treatment plan that 
included orders for GC therapy.  
Process evaluation.  This evaluation focuses on the process of implementing the practice 
change and, thus, focuses on the users of the protocol.  The users included all RN staff and 
oncologists on the two oncology units, who provided care for the inpatients who met the impact 
evaluation criteria.      
 Recruitment/marketing plan.  The recruitment phase was designed with the intent to 
ensure the interest and ultimately, the engagement of the stakeholders in the development, 
implementation, and sustainability of the practice change.  Practice change often requires the 
involvement of diverse skill sets to be successful.  A list of the core stakeholders and their 
contributions to the evaluation plan is delineated in Table 7.  In order to gain recruitment of key 
stakeholders, it is important to have a stakeholder engagement plan in place that attracts a 
multidisciplinary team.   
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Table 7 
How Each Stakeholder Group Will Contribute to the Evaluation 
Stakeholder 
 
Increasing 
credibility 
of the 
evaluation 
Helping 
with the 
design of 
the 
evaluation 
plan 
Implementing 
the 
evaluation’s 
intervention 
Advocate 
for changes 
to 
implement 
evaluation 
findings 
Fund or 
authorize 
action to 
implement 
evaluation 
findings 
PU DNP student X X X X  
PRU Inpatient Diabetes 
Team APRN/DNP 
project content expert 
X X X X X 
P Data Analysts  X X X   
PRU Cancer 
Committees 
X X  X X 
PRU Diabetes Care 
Committee  
X X  X X 
PRU Unit RNs and 
Oncology Unit Nurse 
Managers 
   X X 
Note.  P, R, U describes how each stakeholder is involved in the project: P=Program operations, 
R=Receive services, U=Users of evaluation findings 
 
  Marketing tools should be developed to optimize awareness and recruitment.  With this 
in mind, it became clear that a shorter project title would be more effective in engaging 
stakeholders.  The goal here was not only to create simplicity, but also to equally generate 
memorable qualities.  Thus, the slogan for the protocol was, “Say bye to high…GCIH.”  This 
tagline was fitting since the overall goal of the project was to reduce the rates of uncontrolled 
GCIH.  The accompanying visual included a hand in a waving motion, as if to say “bye,” as seen 
in Appendix D.  This image was featured on the educational tools for the staff.  The Diabetes 
Team APRN approved both the slogan and logo.   
Data Collection Procedures 
Data collection incorporated running data sets based on the established codes from 
electronic medical records (EMR) that identify the specified variables of the targeted population 
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over the baseline and post-implementation time frames.  The Diabetes Team’s designated data 
analyst managed the impact and process evaluation data.  The data analyst holds previous 
experience with data sets and is knowledgeable regarding proper data collection procedures per 
organizational policy.  The proper protocols have been followed in accordance with HIPAA 
regulations in accessing medical records and ensuring that the confidentially of the data is 
maintained when shared with the DNP student and content expert for educational purposes.  
Charts were not individually reviewed and no individual patient chart was targeted.  
Process and Outcome Variables 
A process evaluation was employed to ensure that the intervention was implemented 
accurately.   User adherence was assessed via three proxy measures that are directly related to 
the correct use of the protocol: the number of BGM orders, insulin orders, and Diabetes Team 
consults.  These proxies are positioned as intermediate variables in the impact evaluation because 
of their influence on two prominent measures of patient outcomes: 1) A decrease in hospital LOS 
and 2) The rate of uncontrolled hyperglycemia episodes.  
The impact evaluation used a T1-T2 design.  The T1-T2 design assesses the impact of the 
intervention (independent variable) on the outcomes (dependent variables), by means of 
comparing the baseline data (T1) with the post-implementation data (T2).  This DNP project’s 
impact evaluation explored the relationship between the GCIH protocol and the overall 
hyperglycemic rates in adult oncology inpatients receiving GCs.  The T1 was defined as the 
number of uncontrolled hyperglycemia episodes and was compared to the T2 data.  As suggested 
by the DOC and DCC, ALOS will also be measured to investigate the potential influences of the 
protocol. 
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Because the protocol was implemented in August, baseline data will range from April to 
July 2017, while post-implementation data will cover September to December 2017.  The data 
was collected and analyzed in January 2018.  
Program Evaluation Plan 
Evaluation Question 
Will an evidenced-based protocol for the assessment and management of GCIH increase 
the rates of BGM orders, insulin orders, and Diabetes Team consults, and reduce the overall rates 
of uncontrolled hyperglycemic episodes and hospital ALOS by 25% in adult oncology inpatients 
receiving GC therapy, on the oncology inpatient units over a 4-month period?    
Data Analysis  
With the completion of the implementation and the collection of data, a two-week period 
in January 2018 was allotted for data analysis.  For both the impact and process evaluations, 
descriptive statistics were utilized.  The outcomes involved the calculated difference between the 
T1 and T2 rates.  
The goal was to gain a 25% improvement in all outcome rates compared to baseline.  
However, it is important to reflect on why the outcomes were or were not reached.  The DNP 
student and content expert analyzed the data and jointly interpreted the outcomes in preparation 
for presentation to the stakeholders within the succeeding two months.   
Impact evaluation.  The data analysis plan of the impact evaluation of the GCIH 
protocol involved comparison of the T1 and T2 measures by subtracting the calculated T1 rates 
of uncontrolled hyperglycemia and average ALOS days from the calculated T2 rates.  The data 
set regarding uncontrolled hyperglycemia will demonstrate the total number of patients who met 
inclusion criteria and experienced a BG level ≥ 180 mg/dl.  The data will be divided into 
   
41 
categories designated by the following BG level ranges: 180-299, 300-399, and >400.  The data 
set regarding ALOS will exhibit the calculated days for the patients who met the inclusion 
criteria.  Both data sets were further sub-divided to demonstrate the outcome values based on the 
presence of a Diabetes Team consult in order to assess any correlations.  An improvement in the 
rates would mean a decrease in the number of patients experiencing uncontrolled hyperglycemia 
and a shorter ALOS post-implementation.  
Process evaluation.  The process evaluation data analysis plan similarly entailed a 
comparison of the calculated rates of the baseline and post-implementation outcome measures, 
but with a particular focus on the BGM orders, insulin orders, and Diabetes Team consults to 
measure user adherence.  User adherence to the protocol is demonstrated by an increase in the 
rates of BGM orders, insulin orders, and Diabetes Team consults.   
Resources 
Financial  
Formal financial funding for the DNP project was not provided.  The implementation and 
evaluation of the GCIH protocol were imbedded into the daily routines of the staff RNs, 
oncologists, Diabetes Team, and Diabetes Team data analyst, without additional monetary 
compensation for the added workload.  Additionally, the DNP student was responsible for 
personally funding the production of educational materials for the staff.  
Human 
Educational in-services for the staff, as well as multiple presentations of the project to the 
various approving committees, were completed by the DNP student and the content expert.  Two 
staff RNs from the oncology units were recruited to assist as a staff-level resource for the 
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protocol.  The IT department and oncology pharmacists helped to integrate the protocol into the 
EMR through the BPA.   
The implementation phase of the GCIH protocol involved the oncology unit staff 
including the oncologists, the nurse managers, and approximately 100 staff RNs.  The Diabetes 
Team were also a key resource during implementation when consults were placed.  
The evaluation stage relied heavily on the expertise of the Diabetes Team data analyst, as 
well as the Clinical Data Analysts from the organization’s Center for Outcomes Research and 
Evaluation.  
Time 
Implementation commenced in August 2017 with staff education of the protocol.  These 
educational in-services were 5-10 minutes in duration, however, involved multiple groups of 
RNs at varying times depending on availability based on patient care, and during varying nursing 
shifts.  The goal was to provide education to 100% of the oncology unit RN staff by the end of 
August.  The BPA was officially embedded into the EMR in October 2017.  Therefore, the entire 
implementation phase for the purpose of data collection spanned the four-month period from 
September 2017-December 2017. 
An advanced notice was provided to the data analysts as to the timeline and when his or 
her services would be required.  This strategy helped to prepare the analyst for the added 
workload.  A two-week period in January 2018 was allotted for data collection.  Thereafter, the 
DNP student and content expert analyzed the results for dissemination to the stakeholders within 
the succeeding two months through meetings and organizational forums.    
   
43 
Physical   
To address the resource of physical space, educational GCIH protocol sessions conducted 
by the DNP student and content expert took place in the oncology units within the nursing 
station.  Access to computers is available for staff use at all times.  The data analyst has her own 
office and the necessary computer programs to perform data collection.  Codes that identify the 
requested variables and patient population were established and used to extract the data from the 
EMR.  The content expert has her own office to complete analysis of the data with the DNP 
student.   
Timeline 
An overview of the timeline for the project is featured in Table 8 below. 
Table 8 
Timeline of the Implementation and Evaluation of the DNP project 
 Jun 
‘17 
Jul
‘17 
Aug 
‘17 
Sep 
‘17 
Oct 
‘17 
Nov 
‘17 
Dec 
‘17 
Jan 
‘18 
Feb 
‘18 
Successful defense proposal X         
Develop and distribute 
marketing products  
 X X       
Staff education   X       
Collect baseline data        X  
Implement protocol     X X X X   
Obtain feedback regarding 
protocol 
       X  
Collect post-implementation 
data 
       X  
Analyze data        X  
Make revisions to protocol         X X 
Disseminate results        X X 
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Human Subjects Considerations 
This DNP proposal of the GCIH assessment and management protocol has been designed 
in such a way as to protect the rights of any human subjects involved in the project.  As a quality 
improvement initiative, standard, EB practices were implemented.  The DNP student has 
completed the University of Hawaii required Collaborative Institutional Training Initiative 
(CITI) course in Human Subjects Protection.  A committee consisting of faculty and clinical 
experts reviewed this proposal to ensure there was adequate human subjects protection.  There 
was no additional risk beyond standard practice.  Person-identifiable information will not be 
collected.  The project addressed each of the five nursing ethical tenets: 1) Autonomy, 2) Non-
maleficence, 3) Beneficence, 4) Justice, and 5) Veracity.  Each of these tenets will be explained 
in more detail in the following sections.  
Autonomy 
Autonomy describes an individual’s right to self-determination, with the ability to make 
decisions about their life without external influence from others (Silva & Ludwick, 1999).  The 
project allowed for participant autonomy through the patient’s right of refusal of care.  The 
patient was not mandated to participate in the GCIH protocol. 
Non-maleficence 
Non-maleficence is defined as to do no harm, where the provider and nurse have the 
responsibility to protect the patient’s safety (Silva & Ludwick, 1999).  The providers had the 
ability to discontinue or modify the BGM or insulin orders based on their clinical judgment, 
order duplication, or practice preference.  The provider was able to defer their participation in the 
protocol at any time, if deemed to cause unsafe conditions for the particular patient’s health 
status, or if it affects patient satisfaction. 
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Beneficence 
Beneficence means to promote good and to act in accordance with an individual’s 
welfare (Silva & Ludwick, 1999).  This ethical tenet was addressed by the overall aim of the 
GCIH protocol, to reduce prolonged untreated hyperglycemia that may lead to negative 
outcomes for the oncology patients.  The GCIH protocol was also projected to provide improved 
direction for staff in the management of GCIH. 
Justice 
Justice involves providing each individual fair and equitable access to care and resources 
(Silva & Ludwick, 1999).  The project addressed the ethical tenet of justice, as there was no 
randomization of the sample population to different treatments.  All adult oncology patients who 
met the previously outlined criteria received treatment as guided by the same GCIH protocol. 
Veracity 
Veracity is the principle of telling the truth with full disclosure by providers to patients 
(Silva & Ludwick, 1999).  This ethical principle was addressed through staff and patient 
education of the protocol and notification of involvement in the implementation of the practice 
change. 
Limitations 
Despite efforts to account for risks, there are factors in addition to the proposed protocol 
that may influence outcomes.  Within the setting of a quality improvement initiative, it is not 
realistic that all conditions can be controlled.  
Sample Size and Time 
Firstly, based on the fluidity of the practice change setting, it is not possible to predict the 
precise number of patients who will meet the protocol criteria over the course of the four-month 
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time frame.  Secondly, the two units can only accommodate a total of 48 patients at any given 
time.  This may lead to a small sample size and affect external validity.  Furthermore, the four-
month implementation phase may not be a sufficient amount of time to adequately engage the 
users of the innovation to achieve a sustained practice change.  
Patient Right to Refusal of Care 
For those patients who do not regularly have their BG levels checked, (i.e., they have not 
had a history of DM) they may refuse to have their fingers pricked four times a day, based on the 
protocol indications of BGM.  In that case, it would be unethical to have these patients 
participate in the protocol against their wishes.  Therefore, the protocol may be discontinued, 
again affecting outcomes.  Increasing the patients’ awareness and knowledge of the protocol, as 
well as the importance of managing GCIH, through patient education from the staff will be 
highly encouraged to minimize situations such as this.    
Staffing Considerations 
The expectation of the protocol is that once a Diabetes Team consult is placed, 
hyperglycemia management is immediately initiated.  However, this is may not always be the 
case, based on issues such as staffing levels or workload at the time of the consult.  Members of 
the inpatient Diabetes Team who can assist with hyperglycemia management include two 
APRNs, two Endocrinologists, and one pharmacist.  These five members provide services 
hospital-wide; therefore, hyperglycemia levels may not be promptly managed, depending on 
patient load, which may affect data outcomes.  
Variance in Clinical Judgment and Preferences for Administrative Autonomy 
Although the protocol called for a BPA that recommends the orders of BGM, insulin, and 
Diabetes Team consultation, oncologists still have the capability of deselecting any of these
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options or to discontinue the orders based on their clinical judgment.  In other words, they are 
not bound to the protocol, as it is not an established organizational policy.  Given the fragile 
health state in which oncologic patients face, the potential onset of hypoglycemia episodes could 
act as a deterrence from the protocol.  In addition, those oncologists who prefer managing all of 
their patients’ care orders themselves may not feel comfortable with sharing that control and 
again may defer their participation in the protocol.  Those decisions will likely affect outcomes.  
In line with this, the responsibility to escalate care to the Diabetes Team based on consistently 
elevated BG levels ≥180 mg/dl also lies with the RNs or providers to recognize and act 
accordingly, as per the protocol. 
Factors Impacting ALOS and hyperglycemia 
ALOS will be concurrently evaluated to assess for any correlation with BG levels and 
Diabetes Team consults.  However, this correlation may be an inaccurate measure, as ALOS 
could also be influenced by many other variables such as a patient’s comorbidities.  Additionally, 
hyperglycemia experienced in this patient population could also be similarly influenced by such 
variables as comorbidities, other medications, or stress, all of which are not accounted for in the 
scope of this quality improvement project. 
Summary 
Chapter 3 has described the characteristics of the protocol and has subsequently covered 
the plans for implementation and evaluation, in accordance with the Iowa Model.  Despite the 
presence of limitations due to a lack of control over certain aspects of this EB quality 
improvement initiative, the overall goal remained to create a standardized protocol for providers 
and staff to follow.  This protocol aimed to promote early GCIH detection and initiation of 
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appropriate management measures to reduce the rates of uncontrolled hyperglycemic episodes 
and ALOS experienced by the inpatient hematologic malignancy population receiving GCs.    
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CHAPTER 4: RESULTS 
Objectives 
The final step of the Iowa Model (Titler et al., 2001) is the evaluation of the project, 
which involves monitoring and analyzing of the structure, process, and outcome data.  Chapter 4 
will present the results of both the impact and process evaluations.  An examination of the results 
can assist in determining whether or not the practice change achieved the proposed objectives 
and help to identify areas for improvement.  A description of the resulting sample, as well as a 
trend analysis for the process and outcome variables, are explored.  A reflection of the evolution 
of the project will also be featured through review of the expected versus actual outcomes, along 
with facilitators and barriers that were encountered throughout the completion of this DNP 
project.   
Description of Sample 
 The sample population for the project consisted of adult oncology inpatients with ICD-10 
diagnosis codes for hematologic malignancies, on an active treatment plan that included GCs, 
and who were admitted or transferred to and discharged from either of the two oncology units 
between the specified timeframe.  The baseline group consisted of 75 patients who met criteria 
between April 1, 2017 and July 31, 2017.  The post-implementation group comprised of 49 
patients who met criteria between September 1, 2017 and December 31, 2017.  
Trend Analysis for Process and Outcomes Variables  
Analysis of the process, as well as outcome variables of the practice change, was 
completed by means of process and impact evaluations.  The variables that were measured in the 
process evaluation were BGM orders, insulin orders, and Diabetes Team consults.  The variables 
that were measured in the outcome evaluation were uncontrolled hyperglycemia episodes and 
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ALOS days.  The results of the evaluations involved the calculated difference between the T1 
and T2 rates of the sample and are described in the subsequent sections.      
Process Evaluation 
An improvement in the process evaluation variables: BGM, insulin orders, or Diabetes 
Team consults, would reflect user adherence to the protocol.  These orders are directly related to 
the appropriate use of the protocol, as they needed to be proactively initiated by the users.  An 
improvement would be indicated by an increase in the numbers of these orders in the post-
implementation data as compared to the baseline.  
The process evaluation (see Tables 9, 10, and 11) revealed a 3% improvement in BGM 
orders, as well as an 8% increase in Diabetes Team consults.  There was a 6% decrease in insulin 
orders. 
Table 9 
Baseline (T1) – BGM Orders, Insulin Orders, and Diabetes Team Consults  
Response BGM Orders Insulin Orders Diabetes Team Consults 
Yes 42 27 3 
No 33 48 72 
Totals 75 75 75 
 
Table 10 
Post-implementation (T2) - BGM Orders, Insulin Orders, and Diabetes Team Consults 
Response BGM Orders Insulin Orders Diabetes Team Consults 
Yes 29 14 6  
No 20 35 43  
Totals 49 49 49  
    
Table 11 
T1-T2 Process Evaluation: BGM Orders, Insulin Orders, and Diabetes Team Consults 
 % BGM orders % Insulin Orders % Diabetes Team consults  
Baseline (T1) 56% 36% 4% 
Post-implementation (T2) 59% 29% 12% 
Change Δ +3% -7% +8% 
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Impact Evaluation 
An improvement in the impact evaluation would be defined as a reduction in the number 
of uncontrolled hyperglycemic episodes, as well as a decrease in ALOS days in the post-
implementation data as compared to the baseline.  The improvement would reflect an overall 
reduction in the delay of detection and management of GCIH.  
The impact evaluation presented a 3% decrease in total uncontrolled hyperglycemia 
episodes (See Tables 12, 13, and 14).  There was an improvement in Diabetes Team consults that 
appropriately met criteria, as supported by a 54% increase in the number of uncontrolled 
hyperglycemia episodes with a diabetes team consult.  A 3% decrease in the number of overall 
hypoglycemic episodes was also noted.     
Table 12 
Baseline (T1) – BG Levels in Relation to Diabetes Team Consults  
Consult BG 
≤70 
BG 
71-179 
BG 
180-299 
BG 
300-399 
BG 
≥ 400 
Grand 
Total 
Yes 12 6 50 11 0 79 
No 14 160 173 43 11 401 
Total 26 166 223 54 11 480 
 
Table 13 
Post-implementation (T2) – BG Levels in Relation to Diabetes Team Consults 
Consult BG 
≤70 
BG 
71-179 
BG 
180-299 
BG 
300-399 
BG 
≥ 400 
Grand 
Total 
Yes 5 60 125 34 11 235 
No 7 101 50 5 0 163 
Total 12 161 175 39 11 398 
 
Table 14 
T1-T2 Impact Evaluation: Hypoglycemia and Uncontrolled Hyperglycemia 
 
% 
Hypoglycemia 
% Uncontrolled 
Hyperglycemia 
% Uncontrolled 
Hyperglycemia with consult 
Baseline (T1) 6% 60% 22% 
Post-implementation (T2) 3% 57% 76% 
Change Δ -3% -3% +54% 
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The impact evaluation also revealed that during the post-implementation period, the 
calculated ALOS days (See Tables 15, 16, and 17) decreased by four days for those without a 
Diabetes Team consult and increased by 35 days for those with a Diabetes Team consult.  
Overall, ALOS increased by six days across both groups.   
Table 15 
Baseline (T1) - ALOS in Relation to Diabetes Team Consults 
Consult Cases ALOS (days) 
Yes 3 35 
No 39 24 
Total 42 25 
 
Table 16 
Post-implementation (T2) – ALOS in Relation to Diabetes Team Consults 
Consult Cases ALOS (days) 
Yes 6 70 
No 23 20 
Total 29 31 
 
Table 17 
T1-T2 Impact Evaluation: ALOS 
 
Overall 
ALOS days 
ALOS days 
without consult 
ALOS days 
with consult  
Baseline (T1) 25 24 35 
Post-implementation (T2) 31 20 70 
Change Δ +6 -4 +35 
 
 
The LOS days based on the highest BG level reading during the hospitalization were also 
noted to evaluate any potential correlation between severe hyperglycemia and LOS (See Tables 
18 and 19).  In both the baseline and post-implementation data, the ALOS days were generally 
higher in patients meeting uncontrolled hyperglycemia levels than those with controlled levels of 
less than 180 mg/dl.  These results emphasize that patients that experienced uncontrolled 
hyperglycemia often have prolonged hospitalizations.  
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Table 18 
Baseline (T1) –ALOS Days in Relation to Highest BG Levels 
 BG 
<180 
BG 
180-299 
BG 
300-399 
BG 
≥ 400 
Cases 
Length of stay 
ALOS 
13 14 8 7 
264 334 127 284 
21 24 16 41 
 
Table 19 
Post-implementation (T2) – ALOS Days in Relation to Highest BG Levels 
 BG 
<180 
BG 
180-299 
BG 
300-399 
BG 
≥ 400 
Cases 
Length of stay 
ALOS 
13 9 2 5 
198 206 46 427 
16 23 23 86 
 
Evolution of Project 
 In developing the quality initiative, a plan was established in accordance to The Iowa 
Model (Titler et al., 2001) to guide the successive phases of the project.  Objectives were also set 
for each phase.  However, flexibility was key with execution of the practice change in order to 
adapt to the unanticipated organizational and stakeholder demands.  Table 20 outlines the 
expected versus actual outcomes in relation to the phases of the project based on the IOWA 
model steps.  A description of noted facilitators and barriers to this DNP project will also follow. 
Expected versus Actual Outcomes  
Table 20 
Expected versus Actual Outcomes of the DNP Project 
 Expected outcomes Strategies Actual outcomes 
Forming a 
team 
•   Prior to August 
implementation, 
recruitment of four 
staff RNs on each of 
the oncology units, 
•   Discussed with 
nurse managers the 
potential RN 
candidates to recruit 
•   Two day-shift RN staff 
from one unit finally 
agreed to assist in 
October (after 
implementation) 
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ideally two who 
work the day shift 
and two who work 
the night shift, will 
be sought to assist as 
a staff-level resource 
for the algorithm. 
•   100% support from 
Oncologists and 
Diabetes Team 
•   Emailed and 
personally contacted 
staff on units; 
advertised 
opportunity as a 
means of 
professional 
development 
through the clinical 
ladder program 
•   Attended unit 
council meetings, 
department 
meetings 
•   Presented project 
with triggers, 
supporting data, and 
plan of action 
•   Approval of project 
was obtained by 
Oncology and Diabetes 
groups, however, with 
some reserve from 
select oncologists due 
to lack of strong 
supporting evidence of 
benefit 
Staff 
education 
of protocol 
•   100% RN staff 
educated on the 
protocol within 
month of August 
 
•   In-services for staff 
on unit throughout 
month of August  
•   Algorithm posted on 
unit 
•   Info. added to the 
unit’s morning 
announcements     
•   RN staff education 
limited to one week in 
August per nurse 
manager’s request.  
•   Occurred throughout 
the week of 8/20/17, 
twice a day, seven days 
straight, approximately 
4 hours each day.  In-
services were ~5-10 
minutes in duration 
depending on how 
busy the staff were. 
•   ~70% Oncology unit 
staff and a few Float 
Pool and Crisis RN 
staff received 
education 
BPA 
•   Roll out BPA by 
August 21st, in 
concurrence with the 
staff education 
•   Obtained service 
request approval for 
EMR changes in 
March 2017  
•   BPA production was 
not fully initiated until 
after August due to 
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•   Attended multiple 
oncology meetings 
in 2017 for feedback 
and approval of 
BPA 
•   Closely worked 
with IT and 
Pharmacist on 
design and trial of 
BPA 
organizational upgrade 
in EMR  
•   BPA did not go live 
until October 31.  
Sample 
size 
•   Sample size of 
approximately 100 
patients, based on 
initial background 
data from 1/1/2016 
and 8/31/2016, that 
showed 527 patients.  
This sample, 
however, comprised 
of all oncologic 
diagnoses. 
•   Limited sample 
criteria to 
hematologic 
malignancies per 
Department of 
Oncology request as 
pilot project 
•   Baseline sample: N=75 
•   Post-implementation 
sample: N=49 
Outcomes 
•   Process evaluation:  
25% improvement in 
the baseline rates of 
BGM, insulin orders, 
consults to the 
Diabetes Team.   
•   Impact evaluation: 
25% improvement in 
the baseline rates of 
uncontrolled 
hyperglycemia (>180 
mg/dl) and ALOS 
days. 
•   Developed protocol 
•   Staff education on 
protocol (evidence 
based-algorithm and 
BPA), 
•   Implementation of 
BPA in EMR 
Process evaluation: 
BGM-  
3% increase 
Insulin orders- 
6% decrease 
DM Team consults-  
8% increase 
Impact evaluation: 
Uncontrolled 
hyperglycemia episodes- 
Overall 3% decrease 
ALOS days- 
Overall 6-day increase 
 
 
Facilitators 
Organizational goals.  As a major teaching hospital, the tertiary care center was highly 
supportive of and continuously promotes the integration of EB practice in patient care delivery.  
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The project aligned with two of their organizational goals: 1) Patients First. Be a national leader 
in quality & patient safety and 2) Provider of choice. Ensure the right care, at the right place, at 
the right time. Therefore, the project was approved by the organization’s Clinical Ladder 
Oversight Committee who reviews performance improvement, research, and evidence-based 
practice projects prior to implementation.  
The oncology group, which includes DOC and CSC, is required to meet the Commission 
on Cancer Standard 1.5 Clinical each calendar year.  This standard involves establishing, 
implementing, and monitoring at least one clinical and one programmatic goal for endeavors 
related to cancer care.  This goal facilitated the approval of the project by the oncology 
committees.  
Interdisciplinary stakeholders.  The project protocol was ultimately approved by 
multiple key organizational level committees that served as stakeholders of the practice change: 
The DCC, The Medical Records Committee, and the oncology staff unit council.  Without their 
approval, the implementation of this project would not have been possible. 
Key facilitators of the logistics of the DNP project protocol resulted from the 
collaboration and productive input provided by interdisciplinary departments including 
informational technology (IT) department, the oncology pharmacist, and the data analysts.  With 
their support, the BPA was successfully embedded into the EMR and the data was thoroughly 
collected.          
Barriers 
Time.  A critical barrier to implementation involved the factor of time, as it was essential 
to respect the schedule of the staff and contributing interdisciplinary groups.  It was 
understandable that this DNP project was an added item to their work volume and therefore, not 
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always a priority.  There were unforeseen sick leave and work vacation taken by critical 
supporters of the project that negatively affected the proposed timeline.  
In addition, because the oncology units were engaging in multiple initiatives in 
concurrence to the implementation of this DNP project, the nurse managers limited the staff 
education of the protocol to one, specified week in August.  During that week of staff education, 
the in-service time was constrained by the busy workload of the RN staff.  As a result, only 64% 
of the staff was educated.  This limited timeframe in education, as well as the four-month 
implementation period, was likely insufficient to influence a change in work culture and routine. 
Organizational initiatives.  In September 2017, the organization underwent a massive 
upgrade in their EMR, called Triple Play, to align with industry practice.  Consequently, in the 
months that preceded September, all proposed patient safety initiatives that would require builds 
into the EMR were carefully reviewed and selectively chosen based on urgency and underwent 
scrutiny to obtain approval by executives.  An ultimate hard freeze on all EMR build requests 
went into effect on July 28, 2017.   
Although this DNP project obtained approval by the necessary governing bodies prior to 
the hard freeze date, the IT group and pharmacist, who were key players in creating the BPA, 
were understandably occupied with providing Triple Play Command Center support.  Therefore, 
as a result of the time needed to complete successive trial sessions and revisions, the final BPA 
failed to meet the hard freeze deadline.  Ultimately, despite the implementation of the protocol in 
August through staff education of the algorithm, the BPA was not officially embedded into the 
EMR until October.   
Provider preference.  Although the protocol empowered RN staff to recognize GCIH 
and when to escalate care, the proposal for an RN-driven protocol that would enable autonomy 
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for the RNs to place BGM, SSI, and Diabetes Team orders was rejected.  The oncologists 
preferred that all orders be obtained and directed through a call.  This extra step could have 
contributed to minimal improvement in outcomes. 
Lack of strong evidence.  The initial aim of the project was to implement the protocol 
for all patients with oncologic diagnoses that received glucocorticoids.  However, due to the lack 
of strong supporting evidence for addressing GCIH in the oncology population, as a whole, 
proposing the protocol to the oncology group was met with slight, but recurrent opposition by 
select members.  Most of the data available focused on patients with hematologic malignancies.  
As a result, the oncologists approved the project only if it proceeded with the narrow sample 
group of hematologic malignancy diagnoses.  This affected sample size. 
Summary 
 Chapter 4 has featured the last step of the Iowa Model (Titler et al., 2001) with a 
thorough analysis of the results of the practice change initiative, a comparison of expected and 
actual outcomes, and facilitators and barriers to the success of the project.  Within a four-month 
implementation period, objectives were not entirely met, however, positive trends were 
observed, particularly in the increase in number of consults, decrease in uncontrolled 
hyperglycemia episodes, and reduction in hypoglycemic episodes.  To help ensure the project’s 
progression, a prompt recognition of barriers and resilience was essential in developing action 
plans and pushing forward despite drawbacks.    
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CHAPTER 5: DISCUSSION 
Introduction 
With review of the data results in Chapter 4, it is recognized that continuous analysis and 
modification of the of the practice change should occur to improve processes, as well as project 
outcomes.  Chapter 5 will further examine the results by providing an interpretation of the 
findings, followed by Table 19 that outlines the implications and recommendations of this 
project with integration of the eight DNP Essentials.  This chapter will conclude with plans for 
dissemination and sustainment of the practice change.  
Interpretation of Findings 
Process Evaluation Outcomes 
BGM orders.  BGM was consistently emphasized as the highest priority of the protocol, 
as this was the main tool for early detection and served as the paramount precursor to therapeutic 
interventions for GCIH.  The baseline results that spanned April 1st-July 31st, 2017 showed that 
BGM orders were already being placed 56% of the time, a 9% increase from background data in 
2016, as featured in Table 2.  In the post-implementation period, there was a 3% increase in 
BGM orders. 
With a minimal increase noted in the implementation period, it is possible that a 
Hawthorne effect occurred as a result of attendance at multiple oncology committee meetings 
and oncology staff meetings throughout 2017.  During these meetings, presentations from the 
DNP student and content expert included display of the background data, the proposed practice 
change, as well as frequent requests for feedback of the DNP project initiatives.  These actions 
likely heightened the awareness of GCIH in the oncology population.   
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The minimal improvement could also be attributed to the late implementation of the BPA 
on October 30th, which was midway in the post-implementation period.  The initial 
implementation in August comprised only of an algorithm that relied heavily on the RN being 
proactive to obtain orders.  The BPA provided an alert that subsequently reminded and enabled 
the providers to conveniently order the BGM.  Two months of the BPA may have been 
insufficient to result in a meaningful change.  
 SSI orders.  SSI orders were concurrently recommended with BGM in efforts to limit the 
number of resulting uncontrolled hyperglycemia.  The post-implementation data showed a 7% 
decrease in insulin orders.  This trend could be attributable to the provider’s concern for 
hypoglycemia, which was frequently mentioned in the oncology meetings.  Incidentally, there 
was a 3% decrease in hypoglycemic episodes in the post-implementation period.   
Another reason could be the contrary where the provider may not have been concerned 
about GCIH in the patient and made the decision to not place insulin orders.  However, the 
number of patients with BGM orders was higher than the number of patients with insulin orders, 
which means a degree of concern for GCIH must have been present.  It would be interesting to 
explore reasons with the providers for ordering BGM without accompanying treatment.    
Diabetes Team consults.  Diabetes team consults were encouraged to optimize 
hyperglycemia management.  However, per the protocol, providers and RNs were advised to 
place consults for patients when BG levels remained consistently greater than 180 mg/dl, despite 
receiving SSI, in order for the team to assist with BG management.  Therefore, although more 
consults are welcomed, a low number of consults does not necessarily indicate a negative 
outcome.  It could infer that patients are not reaching the >180 mg/dl BG level to meet criteria 
for consults, which indicates user adherence.   
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There was an 8% increase in Diabetes Team consults in the post-implementation period.  
In evaluating the rates of appropriately placed consults per hyperglycemic criteria, there was an 
improvement as compared to baseline.  This improvement was evident by a 54% increase in the 
number of uncontrolled hyperglycemia episodes with a Diabetes Team consult.   
Within this facility, RNs may autonomously place a consult to assist with glycemic 
management and diabetes education.  However, for the purposes of this pilot initiative, the 
oncologists specifically requested for the RN to call for consult orders.  Proposing consistency 
with the organization for the oncology units in regard to the RN-driven protocol for Diabetes 
Team consults for further implementation may result in greater improvement in consults.  
Impact Evaluation Outcomes 
 Uncontrolled hyperglycemia episodes.  The post-implementation data showed a 3% 
decrease in total oncology inpatients with BG levels greater than 180 mg/dl.  This result could 
indicate the positive impact of the GCIH protocol on GCIH detection and management, but there 
is room for improvement.  With promotion of early detection and management, a reduction of 
overall uncontrolled hyperglycemia rates could ensue. 
ALOS days.  The post-implementation data showed a significant increase in ALOS days 
for patients with Diabetes Team consults, a decrease in ALOS days for patients without a 
consult, and an overall ALOS increase of six days.  At baseline, there was an 11-day difference 
in ALOS between the Diabetes Team consult group and those without one, while in the post-
implementation data, there was a 50-day difference.  This variability emphasizes the challenge in 
concluding a direct correlation of the presence of a Diabetes Team consult or lack thereof with 
ALOS.  
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In both data sets, patients with a Diabetes Team consult experienced longer ALOS days.  
There are many other contributing factors to prolonged hospitalization, including the admission 
diagnosis, prognosis, comorbidities, and disposition.  Furthermore, the presence of a Diabetes 
Team consult could equally infer that the patient requires more complex care management, as 
consults are typically placed by providers for supplementary management.  These factors are not 
accounted for in the scope of this quality improvement project.  In the future, it may be 
advantageous to examine any correlations between uncontrolled hyperglycemia levels and other 
patient outcomes such as infection/sepsis rates.     
 Overall, with the resulting sample size of 49, trends can be noted, however the data is not 
strong enough to produce conclusions.  Because it is difficult to predict sustainability solely from 
initial implementation results, it will be beneficial to conduct sequential evaluations at varying 
periods throughout the successive implementation processes.  Optimally, a growing database will 
support approval for project expansion.  
Implications and Recommendations for DNP Essentials  
Doctoral graduates in nursing practice are expected to possess a foundational 
understanding of the DNP essentials as outlined by the American Association of Colleges of 
Nursing (2006).  Table 21 describes the integration of the eight DNP essential competencies 
within the development, implementation, and evaluation of this project.  
Table 21 
Implications and Recommendations for DNP Essentials 
DNP Essentials Implications and Recommendations 
Essential I: Scientific 
Underpinnings for Practice 
•   Increased awareness of GCIH significance and 
empowered staff to proactively assess and manage GCIH 
•   Improvement in GCIH detection and management and 
reduction in the rates of uncontrolled hyperglycemic 
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episodes experienced by the inpatient oncologic 
population receiving GCs 
Essential II: 
Organizational & Systems 
Leadership for QI & 
Economics 
•   Alignment with organizational goals 
•   Gained understanding of the organizational workflow, 
rigorous practice change approval processes 
 
Essential III: Evidence-
Based Practice/Translation 
Science 
 
•   Literature critique and synthesis 
•   Integration of evidence-based knowledge, clinical practice 
guidelines, and expert opinion from healthcare providers 
to develop the GCIH protocol 
•   Utilization of the Iowa Model to guide the progression of 
the project and translate evidence into practice 
 
Essential IV: Information 
Systems/Technology 
 
•   PubMed and CINAHL databases for literature search 
•   Creation of BPA through IT support 
•   EMR used to extract datasets 
 
Essential V: Health Care 
Policy & Ethics 
•   Addressed each of the five nursing ethical tenets: 1) 
Autonomy, 2) Non-maleficence, 3) Beneficence, 4) 
Justice, and 5) Veracity. 
•   Advocated for oncology patients experiencing GCIH to 
prevent adverse outcomes 
 
Essential VI: Inter-
professional Collaboration 
 
•   Collaboration with interdisciplinary departments including 
IT, Oncology group (DOC, CSC, Oncologists, Pharmacist, 
staff/managers), Diabetes Group (DCC, Diabetes Team), 
and data analysts. 
 
Essential VII: Prevention 
and Population Health 
 
•   Development of a standardized process for prompt GCIH 
recognition and treatment intended to reduce the incidence 
of uncontrolled GCIH and prevent adverse outcomes that 
may result from GCIH. 
 
Essential VIII: Advanced 
Nursing Practice & 
Education 
 
•   Use of evidence-based standards of care, clinical 
judgement, and collaborative professional relationships to 
produce and implement GCIH protocol  
•   Increased awareness of GCIH significance and 
empowered staff to proactively assess and manage GCIH 
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Plans for Dissemination  
The aim of the dissemination plan is to ensure that the stakeholders adequately 
understand the findings of the evaluation to support further plans for implementation.  Securing 
approval from the key stakeholders to progress towards organizational implementation is the 
ultimate goal.  The DNP student and the content expert will perform dissemination of the 
findings to the organization.  
Dissemination of the evaluation findings to the DCC, the DOC, the Cancer Committee, 
and the oncology unit staff is projected for March 2018.  The presentation of findings will be 
centered on the impact evaluation results to confirm the degree of the protocol’s success.  
Additionally, the results of the process evaluation will be shared to support the impact evaluation 
findings.  Feedback will be obtained regarding the protocol itself, the process, and any barriers to 
future implementation plans involving a larger population.  Revisions to the protocol and 
delivery of education for the protocol will be made based on these responses.    
Organizational dissemination of results will commence in June 2018 at the Nursing 
Grand Rounds, which occurs monthly on the third Thursday and features three, hour-long time 
slots dispersed throughout the day.  This forum is open to all staff, however the topics are 
primarily targeted towards the nursing and advanced practice nursing audiences.  Organizational 
dissemination provides an opportunity to gain larger-scale recruitment of key internal and 
external stakeholders.  
 To bring dissemination to a greater audience beyond the organization, another forum for 
the project is the American Organization of Nurse Executives Conference.  This is an ideal 
opportunity to reach out to other members of the profession statewide and share the findings of 
the project.  Participation in this conference may encourage members of other organizations to 
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assess the status of GCIH in their own settings and pursue the implementation, which could 
generate further support for the project.  Equally, suggestions for this DNP project may arise 
based on GCIH protocols that have already been established.  Finally, to potentially take 
dissemination nationwide, submission of a manuscript to an RN and APRN peer-reviewed 
journal will be done. 
Plans for Sustainment 
The sustainability of the initiative has the potential to be an equally, if not more 
challenging, feat than the initial proposal process.  New initiatives are continually being 
introduced; therefore, to promote lasting change, it is essential for the value of the change itself 
to be internally owned by the stakeholders, rather than externally driven.  In order to instill this 
internal value, direct involvement and active engagement with all types of adopters will be 
necessary to emanate enthusiasm for the GCIH protocol and foster understanding of the 
innovation.  Continual process evaluations will be conducted, with consideration of all feedback 
for improvement.  
With progression towards organizational implementation, more team members will be 
recruited to assist with process evaluations and marketing.  Marketing the GCIH protocol as a 
project opportunity for potential clinical ladder RNs will strategically be used.  The clinical 
ladder program is offered at this organization as an opportunity for professional development.  
This program focuses on the recognition of nurses, who aside from clinical excellence, enhance 
and enrich the clinical practice environment through involvement in organization activities such 
as quality improvement projects.  
Support from leadership will also be requested to assist with validating the success of the 
protocol and therefore, serve as motivation for user-adherence.  It will be proposed that an 
   
66 
annual review of the impact and process evaluation data be conducted.  Subsequently, 
celebrations can ensue for those units that are effectively utilizing the protocol as evidenced by 
improvement in rates or continual optimal outcomes.  The units will be acknowledged through 
various incentives approved by the executive team, such as a unit certificate of achievement or 
cafeteria food vouchers.  
Because the BPA had been successfully embedded into the EMR, a degree of change 
sustainment has been solidified.  However, with continual growth of the project, a renewed 
strategic plan will need to be formulated to effectively recruit a new set of stakeholders of 
differing adopter types.  Specific roles for the stakeholders (e.g., marketing efforts) will be 
clearly communicated and outlined.  Peer accountability to promote user-adherence and advocate 
for the project will be emphasized as the main responsibility for the stakeholders.  Optimally, 
this peer accountability will help to empower others to do the same.       
Summary 
In conclusion, this DNP project utilized the seven steps for implementing a quality 
initiative at a large medical organization, as guided by the Iowa Model by Titler et al. (2001).  
The intent of this practice change was to immediately initiate BGM and insulin therapy in 
concurrence with GC orders, thereby aiding in the prompt detection and treatment of GCIH in 
patients with hematologic malignancies on two inpatient oncology units.  It was expected that 
there would be a resulting reduction in uncontrolled hyperglycemia rates and potentially, ALOS.  
Employing an evidence-based standardized protocol for the assessment and management of 
GCIH proved to heighten awareness of GCIH significance and give rise to improvements in 
uncontrolled hyperglycemia levels.  The results helped to reveal promising opportunities for 
change and progress in the standardized process.  However, further benefits for patient outcomes 
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associated with GCIH management needs to be additionally explored.  Concluding with plans for 
dissemination and sustainability are critical in the ultimate success of this project, which will be 
signified by organizational implementation for all patients receiving GCs.  
  
   
68 
References 
American Association of Colleges of Nursing. (2006). The essentials of doctoral education for 
advance nursing practice [PDF document]. Retrieved from 
http://www.aacn.nche.edu/publications/position/DNPEssentials.pdf 
American Diabetes Association. (2015). Diabetes care in the hospital. Diabetes Care, 39 
(Supplement 1), S99-S104. doi:10.2337/dc16-s016 
American Diabetes Association. (2017). Checking your blood glucose. Retrieved from 
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-
control/checking-your-blood-glucose.html? 
Brady, V. J., Grimes, D., Armstrong, T., & LoBiondo-Wood, G. (2014, November 1). 
Management of steroid-induced hyperglycemia in hospitalized patients with cancer: A 
review. Oncology Nursing Forum, 41(6), 355-365. 
http://dx.doi.org/10.1188/14.ONF.E355-E365 
Brouwers, M., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., . . . 
Zitzelsberger, L. (2013). The AGREE Next Steps Consortium.  Appraisal of Guidelines 
for Research & Evaluation II, 1-11. Retrieved from http://www.agreetrust.org 
Buehler, L., Fayfman, M., Alexopoulos, A.-S., Zhao, L., Farrokhi, F., Weaver, J., … 
Umpierrez, G. E. (2015). The impact of hyperglycemia and obesity on hospitalization 
costs and clinical outcome in general surgery patients. Journal of Diabetes and Its 
Complications, 29(8), 1177-1182. doi:10.1016/j.jdiacomp.2015.07.027 
Corsino, L., Dhatariya, K., & Umpierrez, G. (2014). Management of diabetes and hyperglycemia 
in hospitalized patients. Endotext, 1-26. Retrieved from 
https://www.ncbi.nlm.nih.gov/books/NBK279093/ 
   
69 
Dhatariya, K. (2014). Inpatient glucocorticoid use: Beneficence vs non-maleficence. British 
Journal of Hospital Medicine, 75(5), 252-256. doi:10.12968/hmed.2014.75.5.252 
Dietrich, J., Rao, K., Pastorino, S., & Kesari, S. (2011). Corticosteroids in brain cancer patients: 
Benefits and pitfalls. Expert Review of Clinical Pharmacology, 4(2), 233-242. 
http://doi.org/10.1586/ecp.11.1 
Doody, C.M. & Doody, O. (2011). Introducing evidence into nursing practice: Using the IOWA 
model.  British Journal of Nursing. 20(11), 661-664.  doi:10.12968/bjon.2011.20.11.661  
Fong, A. C., & Cheung, N. W. (2013). The high incidence of steroid-induced hyperglycemia in 
hospital. Diabetes Research & Clinical Practice, 99(3), 277-280. 
doi:10.1016/j.diabres.2012.12.023 
Fuji, S., Kim, S.-W., Mori, S., Kamiya, S., Yoshimura, K., Yokoyama, H., ... Fukuda, T. (2009). 
Intensive glucose control after allogeneic hematopoietic stem cell transplantation: A 
retrospective matched-cohort study. Bone Marrow Transplantation, 44(2), 105-111. 
doi:10.1038/bmt.2008.431 
Gerards, M.C., Tervaert, E.C.C., Hoekstra, J.B.L., Vriesendorp, T.M., & Gerdes, V.E.A. (2015). 
Physician's attitudes towards diagnosing and treating glucocorticoid induced 
hyperglycaemia: Sliding scale regimen is still widely used despite guidelines. Diabetes 
Research and Clinical Practice, 109(2), 246-252. doi:10.1016/j.diabres.2015.05.040 
Gomez, A. M., & Umpierrez, G. E. (2014). Continuous glucose monitoring in insulin-treated 
patients in non-ICU settings. Journal of Diabetes Science and Technology, 8(5), 930-936. 
doi:10.1177/1932296814546025 
Gonzalez-Gonzalez, J. G., Mireles-Zavala, L. G., Rodriguez-Gutierrez, R., Gomez-
Almaguer, D., Lavalle-Gonzalez, F. J., Tamez-Perez, H. E., … Villarreal-Perez, J. Z. 
   
70 
(2013). Hyperglycemia related to high-dose glucocorticoid use in noncritically ill 
patients. Diabetology & Metabolic Syndrome, 5(18), 1-7. doi:10.1186/1758-5996-5-18 
Gosmanov, A., Goorha, S., Stelts, S., Peng, L., & Umpierrez, G. (2013). Management of 
hyperglycemia in diabetic patients with hematologic malignancies during dexamethasone 
therapy. Endocrine Practice, 19(2), 231-235.  http://dx.doi.org/10.4158/EP12256.OR 
Hall, H. R. & Roussel, L. A. (2014). Evidence-based practice: An integrative approach to 
research, administration, and practice. Burlington, MA: Jones & Bartlett Learning.  
Harris, D., Barts, A., Connors, J., Dahl, M., Elliott, T., Kong, J., & ... Sirrs, S. (2013). 
Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients 
undergoing cancer therapy: An observational cohort study. Current Oncology, 20(6), 
e532-e538. doi:10.3747/co.20.1499 
Isbey, C., Gomez, T., & Mooney, C. (2013, November 12). Advanced DSC certification for 
inpatient diabetes care. Retrieved from 
http://www.jointcommission.org/assets/1/6/DSC_teleconference__IPD_111213.pdf 
Jeong, Y., Han, H. S., Lee, H. D., Yang, J., Jeong, J., Choi, M. K., … Kim, S. T. (2016). A pilot 
study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in 
chemotherapy-treated cancer patients. Cancer Research and Treatment  : Official Journal 
of Korean Cancer Association, 48(4), 1429-1437. doi:10.4143/crt.2015.464 
The Joint Commission. (2016). Summary data of sentinel events reviewed by the Joint 
Commission. Retrieved from 
https://www.jointcommission.org/assets/1/18/Summary_2Q_2016.pdf  
The Joint Commission International. (2013). Spotlight on success: Implementing nurse-driven 
protocols to reduce CAUTIs. The Joint Commission: The Source, 11(4), 27-32. Retrieved 
   
71 
from http://www.jointcommissioninternational.org/spotlight-on-success-implementing-
nurse-driven-protocols-to-reduce-cautis/ 
Jung, S.H., Jang, H.C., Lee, S.S., Ahn, J.S., Yang, D.H., Kim, Y.K., ... Lee, J.J. (2014). The 
impact of hyperglycemia on risk of severe infections during early period of induction 
therapy in patients with newly diagnosed multiple myeloma. Biomed Research 
International, 2014(Article ID: 413149). doi:10.1155/2014/413149 
Kaiser Family Foundation. (2016).  Hospital adjusted expenses per inpatient day.  Retrieved 
from http://kff.org/other/state-indicator/expenses-per-inpatient-
day/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%
22:%22asc%22%7D 
Koskela, H. O., Salonen, P. H., Romppanen, J., & Niskanen, L. (2014). Long-term mortality 
after community-acquired pneumonia—impacts of diabetes and newly discovered 
hyperglycaemia: A prospective, observational cohort study. BMJ Open, 4(8), e005715. 
doi:10.1136/bmjopen-2014-005715 
Lansang, M. C., & Hustak, L. K. (2011). Glucocorticoid-induced diabetes and adrenal 
suppression: How to detect and manage them. Cleveland Clinic Journal of Medicine, 
78(11), 748-756. doi:10.3949/ccjm.78a.10180 
Magaji, V., & Johnston, J. M. (2011). Inpatient management of hyperglycemia and diabetes. 
Clinical Diabetes, 29(1), 3-9. doi:10.2337/diaclin.29.1.3 
Mayo Clinic. (2016). Insulin: Compare common options for insulin therapy. Retrieved from 
http://www.mayoclinic.org/diseases-conditions/diabetes/in-depth/insulin/art-20050970 
Melnyk, B.M. (2004). Integrating levels of evidence into clinical decision making. 
   
72 
Pediatric Nursing, 30(4), 323-325.  Retrieved from
 https://www.ncbi.nlm.nih.gov/pubmed/15511051 
Merriam-Webster Incorporated. (2017). Definition of adherence.  Retrieved from 
https://www.merriam-webster.com/dictionary/adherence  
Narwani, V., Swafe, L., Stavraka, C., & Dhatariya, K. (2014). How frequently are bedside 
glucose levels measured in hospital inpatients on glucocorticoid treatment? Clinical 
Medicine, 14(3), 327-328. doi:10.7861/clinmedicine.14-3-326a 
O’Brien, K., Trindell, M., Tarpley, S., & Wiberg, C. (2014).  Operational and conceptual 
definitions.  Retrieved from https://wn.com/conceptual_vs._operational_definition 
Perez, A., Jansen-Chaparro, S., Saigi, I., Bernal-Lopez, M. R., Miñambres, I., & Gomez-
Huelgas, R. (2014). Glucocorticoid-induced hyperglycemia. Journal of Diabetes, 6(1), 9-
20. doi:10.1111/1753-0407.12090 
Pilkey, J., Streeter, L., Beel, A., Hiebert, T., & Li, X. (2012). Corticosteroid-induced diabetes in 
palliative care. Journal of Palliative Medicine, 15(6), 681-689. 
doi:10.1089/jpm.2011.0513 
Rizzo, E. (2013).  6 Stats on the Cost of Readmission for CMS-Tracked Conditions.  Retrieved 
from http://www.beckershospitalreview.com/quality/6-stats-on-the-cost-of-readmission-
for-cms-tracked-conditions.html 
Roberts, A., James, J., & Dhatariya, K. (2014). Management of hyperglycaemia and steroid 
(glucocorticoid) therapy.  Joint British Diabetes Societies for Inpatient Care, 1-26.  
Retrieved from https://www.diabetes.org.uk 
Rogers, E. M. (2003). Diffusion of innovations (5th ed.). New York, NY: Free Press. 
Seheult, J. N., Pazderska, A., Gaffney, P., Fogarty, J., Sherlock, M., Gibney, J., & Boran, G. 
   
73 
(2015). Addressing inpatient glycaemic control with an inpatient glucometry alert system. 
International Journal of Endocrinology, 2015. doi:10.1155/2015/807310 
Silva, M.C., & Ludwick, R. (1999). Interstate nursing practice and regulation: Ethical issues for 
the 21st century.  Online Journal of Issues in Nursing, 4(2).  Retrieved from 
http://www.nursingworld.org/MainMenuCategories/ANAMarketplace/ANAPeriodicals/
OJIN/Columns/Ethics/InterstateNursingPracticeandRegulation.html   
Storey, S., & Von Ah, D. (2015). Prevalence and impact of hyperglycemia on hospitalized 
leukemia patients. European Journal of Oncology Nursing, 19(1), 13-17. 
doi:10.1016/j.ejon.2014.08.005 
Tamez-Pérez, H. E., Quintanilla-Flores, D. L., Rodríguez-Gutiérrez, R., González-
González, J. G., & Tamez-Peña, A. L. (2015). Steroid hyperglycemia: Prevalence, early 
detection and therapeutic recommendations: A narrative review. World Journal of 
Diabetes, 6(8), 1073-1081. doi:10.4239/wjd.v6.i8.1073 
Titler, M. G., Kleiber, C., Steelman, V. J., Rakel, B. A., Budreau, G., Everett, L. Q., … Goode, 
C. J. (2001). The Iowa framework of evidence-based practice to promote quality care. 
Critical Care Nursing Clinics of North America, 13(4), 497-509. 
Umpierrez, G. E., Hellman, R., Korytkowski, M. T., Kosiborod, M., Maynard, G. A., Montori, 
V. M., ... Van den Berghe, G. (2012). Management of hyperglycemia in hospitalized 
patients in non-critical care setting: An endocrine society clinical practice guideline. The 
Journal of Clinical Endocrinology and Metabolism, 97(1), 16-38. 
http://dx.doi.org/10.1210/jc.2011-2098 
Vu, K., Busaidy, N., Cabanillas, M. E., Konopleva, M., Faderl, S., Thomas, D. A., … Yeung, S.-
C. J. (2012). A randomized controlled trial of an intensive insulin regimen in 
   
74 
hyperglycemic acute lymphoblastic leukemia patients. Clinical Lymphoma, Myeloma & 
Leukemia, 12(5), 355-362. doi:10.1016/j.clml.2012.05.004 
Weiser, M. A., Cabanillas, M. E., Konopleva, M., Thomas, D. A., Pierce, S. A., Escalante, C. P., 
… O'Brien, S. M. (2004). Relation between the duration of remission and hyperglycemia 
during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated 
cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–
cytarabine regimen. Cancer, 100(6), 1179-1185. doi:10.1002/cncr.20071 
  
   
75 
Appendix A 
The Iowa Model for Evidence-Based Practice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from “The Iowa framework of evidence-based practice to promote quality care,” by 
Titler et al., 2001, Critical Care Nursing Clinics of North America, 13(4), 497-509.  
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Appendix B 
GCIH Best Practice Advisory (BPA) 
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Appendix C 
Assessment and management of inpatient GCIH algorithm 
 
no  
   yes    
no  
  
Activation  of  Best  Practice  Advisory  (BPA):  
Orders  for  blood  glucose  monitoring  (BGM)  AC  and  HS    
+  Sliding  scale  insulin  AC  and  HS  
  
Provider  to  consider  
discontinuation  of  BGM  
(*RN  to  call  to  obtain  
orders)  
  
*Resume  BGM  AC  and  
HS  at  anytime  if:  
• Hyperglycemia  
symptoms  are  noted  
• AM  serum  BG  levels  
are  ≥  140  mg/dl  
and/or  
• GC  dosing  increases  
  
Meets  GCIH  diagnosis  
  
Continue  BGM  AC  and  HS  
+  
Sliding  scale  insulin  
  
Provider  to  consult    
the  Diabetes  Team    
(*RN  to  call  to  obtain  orders)  
  
Continue  current  regimen  
All  BG  ≤140  
mg/dl  x  48  hours  
WITHOUT  
receiving  insulin?  
  
Initiation  of  glucocorticoids  (GC)  
 
yes  
  
Continue  BGM    
AC  and  HS  
  
yes  
  
no  
  
BG  levels  remain  
≥180  mg/dl,  despite  
insulin  x  24  hours?  
  
  
AC  BG  ≥  140  or    
HS  BG  ≥180  mg/dl  
for  2  readings  
within  24  hours?  
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Appendix D 
Project logo 
 
Adapted from Popkey. (2017). Emoji.  Retrieved from https://popkey.co/featured/emoji- 
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